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“In a world deluged by irrelevant information, clarity is power.” 




POPULAR SCIENCE SUMMARY OF THE THESIS 
Every 24-hours between 400 and 800 ml of bile passes through the bile duct from the liver to the duodenum 
where it assists in digesting and absorbing the food we consume. Obstruction of this 3-6 mm wide duct not 
only decreases absorption of nutrients but also increases the risk for life threatening infection throughout the 
biliary ductal system. The two most common causes for bile duct obstruction are gallstones and strictures 
(which can be cancerous or non-cancerous). Through time medical science has advanced to allow for better 
access to the relatively inaccessible biliary tree to diagnose and treat obstruction. The bile duct can be reached 
with a camera introduced through the mouth (endoscopy) or via a puncture through the skin and liver 
(percutaneous). An even smaller camera placed through the endoscope (cholangioscopy) has the advantage of 
fitting into the bile duct, allowing for first-hand visualisation of disease located there. Biliary stents are tubes 
made of plastic or metal which are placed through strictures in the bile duct to restore bile flow to the bowel.  
Cholangioscopy is a relatively new technology and as biliary stenting is becoming more widespread, the 
dissertation aims to determine several aspects. Firstly, it explores how cholangioscopy in Sweden assists the 
clinician to diagnose and treat stones and strictures. Secondly, it considers whether harm can be done if 
patients undergo a cholangioscopy procedure. Thirdly, it investigates how bile duct stents perform when they 
are placed in different locations in the bile duct (high vs. low) and lastly, which of an endoscopic or 
percutaneous route for stent placement would be more advantageous for the patient. The Swedish Registry for 
Gallstone Surgery and Endoscopic Retrograde Cholangiopancreatography (GallRiks) was consulted to answer 
some of the questions, while patients in South Africa 
also participated in the research. 
Results showed that cholangioscopy is mostly 
performed in specialised units adapted to the treatment 
of challenging diseases of the biliary tree. It has 
significant value in 63% of patients that undergo such 
a procedure. Most value lies in the treatment of 
gallstones, but a second important function is in the 
diagnosis whether strictures are cancerous. 
Importantly, the research found that there is an 
increased risk for complications if cholangioscopy is 
added to an endoscopic procedure, and that it is a 
specialised procedure in which clinicians become 
more skilled over time. 
Regarding biliary stents, results revealed that 
cancerous strictures located higher in the biliary tree 
are more challenging to treat with more complications 
at the time of stent placement, and a higher risk of 
blockage over time compared to stents placed lower 
down in the bile duct. Endoscopic and percutaneous 
routes for stent placement performed similarly, with 
endoscopically placed stents remaining open for 
longer, probably because more stents could be placed 
at the time of the procedure. Results suggested, however, that the two routes each have advantages as well as 
disadvantages, and in future can be used complimentary rather than competitively.  
In conclusion, it is challenging to manage diseases of the small and inaccessible bile duct. Technological 
advancement together with associated increased clinician skills have resulted in improved diagnosis and 
treatment by means of cholangioscopy and biliary stenting. This, however, comes at the risk of increased 
complications and therefore cholangioscopy should be used for specific indications at specialised units. Both 
endoscopic and percutaneous routes for stent placement perform well but there is a clear increased risk for 










Background: The rapid development in endoscopic technology and associated skills has led to an increase in 
more advanced procedures being performed during endoscopic retrograde cholangiopancreatography (ERCP). 
Knowledge is limited regarding clinical value, integration, and outcomes for single operator 
cholangiopancreatoscopy (SOCP) and endoscopic intervention in the different Bismuth-Corlette (B-C) locations 
in the hepatic hilum. 
Objectives: To determine the clinical value of SOCP in the diagnosis and treatment of complex hepatobiliary 
and pancreatic disease. To describe the nationwide integration of SOCP and the extent to which adverse events 
are influenced when SOCP is added to ERCP. To compare adverse events and reintervention rates after 
endoscopic stenting for malignant obstruction in the distal and hilar locations of the biliary tree. To compare 
outcomes after endoscopic transpapillary (ETP) and percutaneous transhepatic (PTH) stenting in the palliation of 
malignant hilar obstruction (MHO). 
Methods: In study I all SOCP procedures performed between March 2007-December 2014 at a tertiary high-
volume endoscopy unit were separately graded according to a predefined 4-graded scale estimating therapeutic 
value and diagnostic yield.  Study II was a nationwide case-control study nested within the cohort of ERCP 
procedures, with- or without SOCP, and registered in the Swedish Registry for Gallstone Surgery and ERCP 
(GallRiks) between 2007-2012. To assess risk factors for adverse events, multivariate logistic regression was 
performed, and odds ratios (OR) calculated. The GallRiks registry was also utilised in study III where all patients 
undergoing endoscopic stenting for malignant biliary obstruction between 2010-2017 (based on International 
Classification of Diseases (ICD) coding), were included. Kaplan-Meier analysis was employed to calculate stent 
patency and Cox proportional hazard models to calculate the risk for recurrent biliary obstruction after single 
metal stent placement. To compare ETP and PTH drainage approaches, a retrospective deconstructed analysis of 
palliative stenting procedures for MHO at two specialised referral centres over a 5-year period was performed. 
Within-group analyses were performed to explore outcomes for different B-C types and Kaplan-Meier and 
restricted mean survival time analyses were performed to calculate and compare duration of therapeutic success.  
Results: In 365 SOCP procedures, SOCP was found be of pivotal importance in 19% of patients, of great 
clinical significance in 44%, and did not affect clinical decision-making or alter clinical course in 37% of 
patients. In study II a learning curve was observed after first introduction of 408 SOCP procedures, and 
postprocedural adverse events (19.1% vs. 14.0%), pancreatitis (7.4% vs. 3.9%) and cholangitis (4.4% vs. 2.7%) 
were more prevalent when SOCP was added to ERCP. After multivariate analysis, the risk for postprocedural 
adverse events remained (OR 1.35, 95% CI [1.04 - 1.74]). In 4623 ERCP procedures performed for stenting of 
malignant strictures (1364 hilar), adverse events and 6-month reintervention rates were increased after hilar 
stenting compared to distal stenting (17.2% vs. 12.0%, 73.4% vs. 55.9%). On multivariate analysis the risk for 
reintervention was three times higher after single metal stent placement in the hilum compared to the distal 
biliary tree (HR 3.47, 95% CI [2.01-6.00], p<0.001). In 293 patients undergoing palliative stenting for MHO 
(52.2% ETP, 47.8% PTH), access and bridging success in the ETP and PTH groups were 83.5% vs. 97.2% and 
90.2% vs. 84.5%, respectively. Technical and therapeutic success were equivalent between the two groups, but 
duration of therapeutic success was longer after ETP drainage, with a 3-month gain in duration of therapeutic 
success after adjustment for B-C type (95% CI [26-160], p=0.006). Cholangitis rates were equivalent (21.4% vs. 
24.7%), while pancreatitis was more common in the ETP group and deaths more common in the PTH group. 
Conclusions: When added to ERCP, SOCP contributes significant clinical value in 64% of cases. However, 
there is an increased risk of intra- and postprocedural adverse events which, together with a learning curve, 
suggests that it should likely be performed in specialised high-volume centres. Regarding endoscopic 
intervention for MHO, stenting in the hepatic hilum compared to the distal biliary tree is associated with more 
adverse events and decreased stent patency. When comparing palliative ETP with PTH stenting for MHO, both 
approaches have similar technical and therapeutic success, with ETP drainage being more durable. Future studies 
should explore the complimentary role of both approaches in specific B-C types.  
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In healthy individuals between 400-800 ml of bile pass via the bile duct into the duodenum every 
24 hours. The two most common ailments affecting this 3-6 mm inaccessible ductal system are 
gallstones and biliary strictures. Obstruction to the flow of bile leads to upstream dilation, 
secondary bacterial infection (cholangitis), and in time, secondary biliary cirrhosis. Diagnosis as 
to the cause and ways in which to relieve biliary obstruction have posed a challenge to physicians 
for many years. 
The most common benign cause of biliary obstruction is gallstone disease. Gallstones can be 
cholesterol or bilirubinate stones that form primarily in the gallbladder and then migrate into the 
bile duct, or primary intraductal stones that are formed due to stasis and chronic low-grade 
infection. Benign stricture formation (30% of all strictures) can be due to primary sclerosing 
cholangitis (PSC), iatrogenic injury, Mirizzi syndrome, anastomotic fibrosis or associated with 
chronic pancreatitis.1 Choledochal cysts, haemobilia (blood in the biliary system) and 
radiotherapy are rarer causes of benign biliary obstruction. Infections and parasitic infestations 
are predominantly seen in developing countries. Malignant biliary strictures are mostly due to 
pancreatic / periampullary carcinoma or intra- or extrahepatic cholangiocarcinoma (CC). 
Malignant hilar obstruction (MHO) is less frequently caused by gallbladder cancer or centrally 
located hepatocellular cancer.2 Lymphoma and malignancy arising anatomically distant from the 
biliary system can lead to MHO by means of metastasis to periportal lymph nodes or the liver 
parenchyma surrounding the perihilar area. The incidence of both pancreatic adenocarcinoma and 
CC has increased in recent years and, as most patients present at an advanced stage of disease, 
treatment is mostly aimed at palliation of symptoms.3,4 
Imaging of the biliary tree in the 1920s consisted of the oral cholecystogram whereby orally 
ingested iodinated phenolphthalein (selectively secreted into bile) provided radiographic images 
of the gallbladder and bile ducts.5 As the bile duct was not accessed directly, therapeutic 
intervention was not an option. It was not until 1955 when Doubilet and Mulholland injected 
contrast into the ampulla of Vater (transpapillary) during open surgery, that direct access to the 
biliary tract became feasible.6 Their initial images were static and two-dimensional but were soon 
followed by dynamic fluoroscopic imaging and eventual percutaneous biliary access that 
followed 30 years later.7  
Direct fiberoptic visualization of the bowel lumen was first described in 1957 by Basil 
Hirschowitz, and in 1968 McCune was the first to publish a report on endoscopic wire 
cannulation of the bile duct in a living patient.8,9 Rapid advancement in endoscopic technology 
led to the development of the side-viewing duodenoscope.10  
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Figure 1. Endoscopic retrograde cholangiopancreatography (ERCP) combined with single 
operator cholangiopancreatoscopy (SOCP). Adapted and printed with permission from 
Frederik Swahn.  
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Endoscopic retrograde cholangiopancreatography (ERCP) is the process by which a side-viewing 
duodenoscope is used to access the bile duct via the ampulla of Vater in order to obtain 
fluoroscopic images (Figure 1). 
Currently, the most common means of access to the biliary tree is either via an endoscopic 
transpapillary (ETP) approach or a percutaneous transhepatic (PTH) approach. The drive to be 
able to perform therapeutic maneuvers during ERCP led to reports of the division of the sphincter 
of Oddi (sphincterotomy) both in Germany and Japan in the 1970s, allowing wider access for 
insertion of devices into the biliary tree.11,12 In the following years, basic therapeutic mechanisms 
were developed. These were aimed at the removal of stones with balloons or baskets and stenting 
of strictures with plastic or metal stents. 
In 1961, a cholangioscope was introduced directly into the bile duct during open surgery.13 The 
advancement from fiberoptic to video-endoscopes allowed for the development of progressively 
smaller caliber scopes with sustained good image quality. Currently, less invasive peroral 
cholangioscopy can be performed in one of three ways: by directly introducing a cholangioscope 
via the mouth into the ampulla of Vater (direct peroral cholangioscopy), by utilizing a specially 
designed duodenoscope and custom made cholangioscope (mother-baby system), or by means of 
the single operator cholangiopancreatoscopy (SOCP) system. The most common SOCP system is 
the SpyGlassTM Direct Visualisation System (Boston Scientific, USA) that passes through a 
standard duodenoscope and houses three ports: an optical port that allows passage of optical 
fibers for visualisation, an irrigation port that ensures continued optimisation of the visual field, 
and a working port through which instruments can be introduced (biopsy forceps or lithotripsy 
apparatus). Its single operator status has ensured that it is the most widely adopted means of 
performing cholangioscopy in current endoscopic practice. The second-generation digital SOCP 
system was introduced in 2015 and allows for improved resolution and a 110° field of vision. 
Application in the pancreatic duct is increasingly being reported. 
Both the improved visualization of the biliary tree and increased ease of access to the biliary tree 
led to ERCP changing from a previously diagnostic modality to mostly a therapeutic intervention 
in current practice. Nasobiliary drainage was first reported in 1980, with the placement of a 








Plastic stents (PS) have a low cost and 
small diameter (maximum of 12F). A 
tendency to migration and biofilm 
formation results in a limited patency of 3-
6 months (Figure 2). Plastic stents are 
mostly used for temporary or short-term 
stenting of the bile duct as they can easily 
be removed and/or replaced, although 
repeated exchanges decrease quality of life 
and escalate costs. 
 
                Figure 2. Bilateral plastic stents. 
 
Self-expanding metal stents (SEMS) are 10-30 
times more expensive than PS but have a larger 
diameter (10mm/30F on an 8.5F delivery system) 
and thus a patency of 6-12 months (Figure 3). 
SEMS occlusion is mostly due to ingrowth in 
uncovered SEMS (uSEMS) and overgrowth or 
migration in covered SEMS (cSEMS). The 
ingrowth occurring in uSEMS makes removal 
difficult and precludes its use in scenarios where 
temporary stent placement is planned. Similar to 
PS, cSEMS can be removed and are thus 
considered for short-term stenting in benign 
disease. Partially covered SEMS (pcSEMS), where 
the flanges are left uncovered, hope to combine the 
benefits afforded by both uSEMS and cSEMS. 
Regarding ease of placement, the pointed tip and 
thin delivery system on which SEMS are preloaded 
facilitate passage through tight strictures, whilst PS 
passage might have to be preceded by balloon 
dilation of very tight strictures.  Figure 3. Unisectoral self-expanding metal stent. 
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Due to the location of the papilla in the duodenal lumen, distal (periampullary) pathology can be 
accessed under direct duodenoscopic vision, making therapeutic techniques at this site relatively 
straightforward. In contrast, the hepatic hilum can only be indirectly represented on two-
dimensional fluoroscopic imaging or via cholangioscopy. Due to its relative ‘further’ placement 
from the duodenal lumen and endoscopist, therapeutic procedures in the hilar biliary system are 
technically much more challenging. 
Adverse events associated with ERCP are well defined and graded as per consensus agreement.16 
Adverse events include pancreatitis, cholangitis, bleeding, perforation, cholecystitis and 
cardiopulmonary events. Of these, pancreatitis is the most common. Based on large prospective 
series,  accepted adverse event rate after ERCP varies between 3%-10% depending on diagnostic 
or therapeutic intent.17 When more advanced procedures such as cholangioscopy and/or stenting 
are added to ERCP, or when intervention is located in the hepatic hilum as opposed to the 






2.1 THE HEPATOBILIARY SYSTEM 
2.1.1 Biliary anatomy and physiology 
 
In the most commonly encountered anatomy of the biliary tree (56%, type 1), the right anterior 
sectoral duct (draining segments 5 and 8) combines with the right posterior sectoral duct (draining 
segments 6 and 7) to form the short (1 cm) vertically orientated right hepatic duct which is prone 
to tumour involvement (Figure 1).18,19 Confluence of the segmental ducts draining segments 2 
and 3 form the left lateral sectoral duct at the umbilical fissure. This duct receives variable 
drainage from segment 4 to end in the left hepatic duct. The longer (3 cm) and horizontally 
orientated left hepatic duct runs in the peritoneal sheath of the hilar plate. The extrahepatic biliary 
tree is formed by the confluence of the left and right hepatic ducts to form the common hepatic 
duct, giving origin to the common bile duct after receiving drainage from the cystic duct. The 
most common variant (14%, type 2) involves a confluence of the right anterior and posterior 
sectoral ducts with the left hepatic duct, and with an absent right hepatic duct. Variable drainage 
of the two right-sided sectoral ducts into the left hepatic duct and common hepatic duct have been 
described as types 3 (20%) and 4 (10%) respectively. 
It is known that the liver is drained by the right hepatic duct (55-60%), the left hepatic duct (30-
35%) and tributaries from the caudate lobe (10%). Computed tomography liver volumetry in 
patients undergoing imaging for unrelated disease has established that, in general, the right liver 
contributes two thirds to total liver volume and the left liver one third.20 In 75% of patients 
segments 2 and 3 together contributed less than 20% of total liver volume. Although 
proportionally the right liver usually contributes more to total liver volume, it is important to note 
that considerable variation is found between individuals. The right liver contribution ranges 
between 49%-82% and the left liver between 17%-49%. 
2.1.2 Definitions and classification 
 
There has been more than one attempt at defining the distal extrahepatic bile duct. Some authors 
refer to the distal third (intrapancreatic portion only), while the Japanese Society of Hepato-
Biliary-Pancreatic Surgery refers to the distal half.21,22 The recent international Asia-Pacific 
Consensus Meeting defined a distal stricture as “an abnormal narrowing of the distal half, which 




Regarding anatomical classification of 
the proximal extrahepatic bile duct, the 
Bismuth-Corlette (B-C) classification 
system was originally developed in 
1975 to assist the operating surgeon in 
deciding on the degree of biliary tree 
involvement in order to plan the 
location for anastomosis after resection 
for malignant disease in the hepatic 
hilum (Figure 4).24 The classification 
system, in its original and modified 
format, refers to the most distal extent 
of normal biliary mucosa available for 
anastomosis.25 With reference to 
malignant stricture classification, the 
loss of communication between the left 
and right liver (hilar block) is classified 
as a B-C II subtype. Bismuth-Corlette 
IIIa and IIIb indicate extension of the 
tumour into the right and left hepatic 
ducts respectively but without clarity on 
whether sectoral ducts are 
communicating. 
     Figure 4. The Bismuth-Corlette classification system. 
Since the introduction of the B-C classification system, it has been applied as the starting point 
for anatomical reference to the hepatic hilum in many clinical scenarios, most notably strictures 
encountered after iatrogenic bile duct injury (Table 1).26 In this setting, and in contrast to its use 
in malignant stricture classification, B-C I-III strictures allow for communication between the left 
and right liver, with separation indicating a B-C IV stricture. Several authors (eg, Strassberg, 
McMahon, and Way) have developed adaptations to include accompanying injuries, to stratify 
severity and to describe mechanism of injury. Costamagna et al., in a modification of the B-C 
classification system, attempted to marry B-C types to drainage strategy by indicating the 
theoretical number of stents required for drainage of 100% of liver volume.27 Their approach 
assumes a hilar block for B-C II types and a right- and left-sided sectoral duct block for B-C IIIa 
and IIIb types, respectively, but does not account for the 40% of patients with an aberrant right-
sided sectoral duct that drains into the left hepatic duct or common bile duct. 
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Table 1. The evolution of the Bismuth-Corlette classification system and its application in hilar 
pathology. 
 Bismuth-Corlette Classification 
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Most gallstones are cholesterol (90%) or pigmented stones (10%). Pigmented stones can be either 
‘black’ bilirubinate stones or ‘brown’ infected stones. Cholesterol and bilirubinate stones form 
primarily in the gallbladder (cholecystolithiasis) but can find their way to the bile duct (secondary 
choledocholithiasis), while brown pigmented stones form in infected bile ducts (primary 
choledocholithiasis).28 Gallstones that migrate from the gallbladder into the bile duct can pass 
through the ampulla of Vater spontaneously. This process may be asymptomatic, or gallstones 
may become lodged in the bile duct leading to obstruction. Most bile duct stones (90%-95%) are 
successfully removed by means of ERCP with biliary sphincterotomy (endoscopic division of the 
sphincter of Oddi) and balloon extraction, with the term ‘difficult’ bile duct stone assigned to the 
5%-10% of stones resistant to removal by ‘conventional’ ERCP techniques.29 There are several 
techniques that can be utilised for the endoscopic removal of “difficult” stones. Endoscopic 
papillary large balloon dilation (EPLBD) entails the insufflation of a 12-20 mm balloon inside the 
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ampulla of Vater to facilitate the passage of larger stones. Mechanical lithotripsy allows for the 
crushing of large stones by closing a wire basket over a captured stone.  
There are currently more than 15 available society/consensus guidelines regarding the treatment 
of cholelithiasis, all with varying definitions of a ‘difficult’ bile duct stone and ‘conventional’ 
methods for stone removal. Stone attributes that render simple balloon extraction difficult include 
size (> 1.5 cm), number (multiple), shape (barrel-shaped), anatomical location (intrahepatic or in 
the cystic duct) or stones that have become impacted due to narrowing or angulation of the bile 
duct. Some guidelines include EPLBD and mechanical lithotripsy as conventional methods for 
stone removal, but most agree that intraductal treatment by employing cholangioscopy constitutes 
advanced therapy.30 Either hydraulic or laser lithotripsy can be performed at the time of 
cholangioscopy, and although no comparable studies are available, success rates are similar in 
reported observational studies.31 
2.2.2 Primary sclerosing cholangitis 
 
Primary sclerosing cholangitis (PSC) is a chronic autoimmune disease resulting in progressive 
intra- and/or extrahepatic bile duct fibrosis and widespread structuring, with a lifetime risk of 
developing CC of up to 30%.32 A dominant stricture is cholangiographically defined as a stricture 
of ≤ 1.5 mm in the common bile duct and ≤ 1 cm in the right or left hepatic duct.33 The presence 
of a dominant stricture carries a high risk for subsequent development of CC (particularly 
perihilar). An indeterminate stricture is generally defined as one where radiological imaging and 
conventional ERCP fail to definitively determine the benign or malignant nature of the stricture. 
2.2.3 Cholangiocarcinoma  
 
The Asia-Pacific region has the highest prevalence of CC.34 However, the incidence in Europe 
and the United States has increased over the past few years.3,35,36 After hepatocellular cancer, CC 
is the most common hepatic malignancy, and after pancreatic adenocarcinoma, it is the most 
common cause of malignant distal biliary obstruction. 
Many classification systems exist, with the most universal being the anatomical classification of 
intrahepatic, perihilar (most common) and distal.37 Perihilar CC is defined as originating from 
cholangiocytes above the cystic duct and below second-order bile ducts (sectoral ducts) and can 
be morphologically subclassified according to growth pattern into mass forming, periductal 
infiltrating (most common) or intraductal types.38 Pathological classification recognises three 
distinct subtypes: sclerosing (70%), nodular (20%) and papillary (5%–10%). Risk factors for the 
development of CC are chronic biliary inflammation associated with Hepatitis B and C infection, 
PSC, Caroli’s disease, liver fluke infestation, hepatolithiasis and bilio-enetric anastomotic 
 
 11 
reconstruction.39 Patients usually present with painless obstructive jaundice (90%) and rarely 
cholangitis (10%). Computed tomographic and magnetic resonance imaging provide confirmation 
of an underlying biliary stricture and assist in staging. The diagnostic challenge lies in confirming 
whether the underlying stricture is malignant. Tumour markers (CA19-9 and CEA) can be falsely 
elevated or negative (10%), brush cytology at the time of ERCP is confirmatory in less than 40% 
of cases, and the addition of fluoroscopically guided biopsies or fluorescent in situ hybridization 
(FISH) increases sensitivity to no higher than 60%.37,40 Up to 40% of patients remain with 
diagnostic uncertainty, risking unnecessary hepatectomy. Based on observational studies, current 
guidelines support the use of SOCP for intrinsic strictures, while endoscopic ultrasound-guided 
fine-needle aspiration is suggested for lesions where external compression or a mass lesion is 
present.41 
There are currently two staging system in use for perihilar CC. The Memorial Sloan Kettering 
Cancer Centre (MSKCC) system considers B-C classification (tumour extent), portal vein 
involvement and the presence of lobar atrophy.42 The American Joint Committee on Cancer 
(AJCC) staging system takes the size and extent of the tumour as well as lymph node and distant 
metastasis into consideration.43 This assists with determination of resectability. Surgical resection 
is the only option for cure, however, most patients (60%-80%) presenting to specialised centres 
are diagnosed at an advanced stage and qualify for palliative biliary drainage rather than resection 
or transplantation.42 Treatment goals are specific to the preoperative or palliative setting, with 
palliation consisting largely of biliary drainage.44 




In a 2007 meta-analysis of 21 studies, Andriulli et al. determined an overall adverse event rate 
after ERCP of 6.9%, with pancreatitis the most common at a rate of 3.8%.17 Seventy-six percent 
of pancreatitis cases were graded as mild to moderate and 24% as severe.  The associated 
mortality rate was 3%. The origin of the current definition of pancreatitis dates back to a 2007 
consensus meeting and has been widely accepted in clinical practice (Suppl. Table 1).45  
Pancreatitis is defined as a serum amylase or lipase of at least 3 times above the upper limit of 
normal, 24 hours post-procedure, accompanied by new onset abdominal pain consistent with 
pancreatitis, symptoms severe enough to require a hospital stay (or extend stay if already 
hospitalised) and/or abdominal computerised tomography scan consistent with the diagnosis of 
acute pancreatitis. It is postulated that pancreatitis is triggered by an ERCP induced event leading 
to pancreatic ductal hypertension by means of direct mechanical, chemical, thermal, hydrostatic, 
enzymatic or microbial injury to the pancreatic ductal epithelium. Although results from 
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observational studies differ somewhat, patient and procedure-related risk factors for the 
development of pancreatitis have been identified in two recent systematic reviews evaluating 
seven and eighteen risk factors, respectively.46,47 A large multicentre randomised controlled trial 
(RCT) investigated the administration of rectal non-steroidal anti-inflammatories (NSAIDs) post-
ERCP in high-risk cases.48 The authors found that in 602 patients, rectal indomethacin reduced 
the incidence of pancreatitis from 16.9%-9.2%. These results have been confirmed in subsequent 
RCTs and 27 meta-analyses and currently form part of most guidelines as part of 
chemoprevention (also for average-risk patients in whom no contra-indication exist).16,49 
Aggressive hydration and sublingual nitrates are options in patients with a contraindication to 
NSAIDs, while prophylactic pancreatic stenting is reserved for high-risk patients (pancreatic wire 
passage or contrast injection).16  
Updated European Society of Gastrointestinal Endoscopy (ESGE) guidelines suggest defining 
additional ERCP-related adverse events according to the 2010 American Society for 
Gastrointestinal Endoscopy (ASGE) lexicon and cholecystitis according to the revised 2018 
Tokyo guidelines (Suppl. Table 1).16,45,50 
2.3.2 Cholangitis 
 
Cholangitis is defined as a temperature above 38°C for more than 24 hours in the presence of 
cholestasis. The incidence of post ERCP cholangitis is low (1%).16 As a result of a landmark 
publication in 2008, there has been a move away from routine administration of antibiotic 
prophylaxis prior to ERCP.51 For some time, incomplete drainage has been known to be a risk 
factor for the development of cholangitis.52 Patients with PSC are at increased risk for cholangitis 
with reported rates ranging from 2.4%-4.0%.53,54 One recent retrospective, single centre report on 
4324 patients aimed to identify independent risk factors for the development of cholangitis.55 
Hilar obstruction, age ≥ 60 years and a history of previous ERCP were listed as significant risk 
factors. The investigators did not include patients in whom cholangioscopy was added to the 
ERCP procedure. Evidence regarding the relationship between cholangioscopy and cholangitis 
risk will be explored later in this chapter. Incomplete biliary drainage (hilar obstruction and PSC) 
and the addition of cholangioscopy is currently recognised as risk factors for post ERCP 
cholangitis.16 Prophylactic antibiotics are advocated in cases where incomplete drainage is 






Universal grading of adverse events assists with comparison of research results and is constantly 
evolving. A grading system for the common ERCP associated adverse events has been suggested 
where: grading of pancreatitis is according to the Atlanta classification for pancreatitis, grading of 
cholangitis and cholecystitis according to the 2018 Tokyo guidelines, and grading of other ERCP-
related adverse events remain according to the 2007 ASGE lexicon.16,45,50,56,57 
2.4 SINGLE OPERATOR CHOLANGIOPANCREATOSCOPY 
 
Since the first bench simulations and feasibility studies reported by Chen et al. in 2007, SOCP in 
its second-generation digital format has evolved to become the most widespread system currently 
in use.58,59 Although many applications for SOCP have been described, established indications 
include the treatment of ‘difficult’ bile duct stones and the diagnosis of indeterminate strictures.60 
2.4.1 Therapeutic single operator cholangioscopy 
 
For treatment of the 5%-10% ‘difficult’ bile duct stones not removed by means of conventional 
ERCP, SOCP has been combined with electrohydraulic and laser lithotripsy since the late 
1980’s.31 Ongoing reports on SOCP use in the primary treatment of large stones (> 1 cm), and its 
ability to diagnose ‘hidden’ stones escaping detection at ERCP and non-invasive imaging, 
promise continuous possible benefit in both simple and complex cases.61–63 
A 2015 meta-analysis, reviewing 49 studies (33 addressing difficult bile duct stones and 29 
addressing indeterminate strictures), reported an estimated overall stone clearance rate of 88% for 
all types of cholangioscopy assisted stone removal.64 More recent pooled and multicentre studies 
report SOCP single-session stone clearance rates between 70%-80%, with 94% eventual stone 
clearance and the pooled number of sessions to stone clearance as 1.26.65,66 Temporary 
endoscopic stenting between SOCP treatment sessions allows friction to be generated between the 
stent and stones, and can assist with stone fragmentation.67,68 The requirement for additional 
treatment sessions, however, remains a limitation.  
Guidelines regarding an approach to ‘difficult’ bile duct stones currently suggest the use of 
endoscopic sphincterotomy and EPLBD as first-line treatment for stones not removed with initial 
simple balloon sweep, and mechanical lithotripsy or SOCP assisted lithotripsy if EPLBD fails or 
is contraindicated.29 Guidelines are based on randomised comparisons of SOCP with both EPLBL 
and mechanical lithotripsy.69–71 These studies report superior or similar stone clearance rates, with 
significantly shorter procedural times favouring conventional ERCP techniques. Surgery is 
reserved for when endoscopic intervention fails or is not available.  
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2.4.2 Diagnostic single operator cholangioscopy 
 
Specificity and sensitivity of ERCP brush cytology and fluoroscopic-guided biopsy can reach up 
to 60%, however, SOCP has received considerable attention as a means to avoid the 7%-25% 
unnecessary resections performed for undiagnosed benign pathology.72,73 It can assist in definitive 
diagnosis of indeterminate biliary strictures in one of two ways: firstly, by means of visual 
inspection, and secondly, by means of tissue acquisition with directed biopsies. 
No standardised classification system exists to guide image interpretation when visually assessing 
indeterminate strictures and reports on its accuracy vary. In observational studies, the accuracy of 
visual inspection ranges from 83%-91%, while the accuracy for SOCP targeted biopsies range 
from 79%-96%.64,74 Despite the expectation that these statistical measures would improve over 
time due to evolving technology, a recent large Japanese multicentre study reported lower overall 
accuracy for SOCP biopsies (70.7%).75 Attempts at on-site vs. off-site processing of these small 
tissue samples and the use of cell-block technology has little impact on accuracy.76,77 Two recent 
meta-analyses reporting on the accuracy of SOCP biopsies and including 539 and 356 patients, 
respectively, found the pooled sensitivity and specificity to be 72%-74% and 98%-99%.78,79 
Single operator cholangiopancreatoscopy application in patients with PSC not only aids in 
confirmation of the nature of the stricture but also assists in traversing otherwise inaccessible 
strictures, enabling dilation and/or establishment of adequate drainage.80 
2.4.3 Single operator pancreatoscopy  
 
Compared to the bile duct, maneuvering of the cholangioscope into the pancreatic duct is more 
challenging. Nonetheless, reports on the role of SOCP in pancreatic stone treatment and the 
management of intraductal papillary mucinous neoplasms (IPMN) are promising. Limited small 
prospective studies (none randomised) report successful pancreatic stone clearance rates of 
between 37%-100%, with an adverse event rate of 0%-30%.81,82 Single operator 
cholangiopancreatoscopy has special application in patients with suspected IPMN and has 
recently been incorporated into consensus guidelines.83 It assists with differentiation of IPMN 
from chronic pancreatitis and determines the extent of main duct involvement pre- or 
intraoperatively. Evaluation of 44 patients with IPMN undergoing pre-operative SOCP found the 
diagnostic accuracy to vary from 76% (main duct type) to 78% (branch duct type).84 The promise 
of pre-operative diagnostic confirmation was, however, offset by a post-ERCP pancreatitis 
incidence of 17%. A more recent retrospective series spanning reported combined visual 
impression and SOCP-guided tissue sampling accuracy between 90%-95%, with an adverse event 
rate of 12%.85 Reports on the use of SOCP in the pancreatic duct are, however, from high-volume 
centres and experienced operators, and therefore efficacy figures might be overestimated.  
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2.4.4 Clinical value of single operator cholangiopancreatoscopy  
 
Whereas clinical utility of a novel procedure can be measured by effectiveness such as calculation 
of a stone clearance rate or diagnostic accuracy estimation, these measures speak to procedure 
performance. Quantifying the clinical value or impact that a new procedure contributes to patient 
care is more complex. Reports on the clinical value of SOCP are limited. An early retrospective 
multicentre series reported successful provision of treatment in 87% of patients with stone disease 
and modification of treatment in 69% of patients with indeterminate strictures.86 The authors 
failed to provide methodological details of how the diagnostic impact of SOCP was assessed. In 
the first multicentre report on the use of SOCP, Chen at al. reported a change in patient 
management in 64% of patients, as assessed by the attending investigator.87  
Three recent studies comprising relatively small sample sizes, assessed the impact of SOCP on 
patient management in cases of indeterminate strictures.88–90 The first report evaluated 13 SOCP 
procedures with a change in patient management after the procedure as a secondary outcome.88 
The authors indicated that SOCP permitted exclusion of malignancy and, as such, avoided 
surgery in 9 patients (69%). Prat et al., in their multicentre study on the impact of SOCP use on 
patient management, included 61 patients and calculated the percentage of patients in whom 
SOCP changed outcomes favourably.89 For each patient the investigators established: (a) planned 
management before SOCP vs. management after definitive diagnosis, and (b) planned 
management after SOCP vs. management after definitive diagnosis. Based on predefined criteria 
for adequacy between diagnosis and management, two teams (investigators and independent 
experts) rated all patients. They found that the addition of SOCP changed management in 60% of 
patients. De Vries et al. estimated the impact on patient management in 77 patients undergoing 
SOCP for evaluation of an indeterminate stricture.90 The author reviewed records and classified 
management of patients into one of three categories: changed (17%), confirmation of planned 
management (51%) or no influence on management approach (32%). Forty percent of the patients 
had PSC, where the pretest probability for malignancy is known to be < 5%, likely explaining the 
lower impact in this study.91 
Regarding the clinical value of SOCP application in the pancreatic duct, reports are from small 
patient samples. Single operator cholangiopancreatoscopy used to guide intra-operative extent of 
surgical resection in patients with IPMN has been reported in 21 patients.92 Occult disease was 
diagnosed in eight and operative strategy was altered in five (23.8%). The value of SOCP in 
planning the extent of surgical resection was evaluated in 18 patients with IPMN.93 Four patients 
(31%) had more extensive surgery, and 4 patients (31%) had less extensive surgery after SOCP 
examination than was initially planned. 
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2.4.5 Adverse events after single operator cholangiopancreatoscopy  
 
Most publications on SOCP outcomes reflect efficacy studies from single, high-volume tertiary 
centres, complicating interpretation of reported adverse events. A multicentre study from the 
United States (available only in abstract format) included 224 SOCP procedures.94 The primary 
outcome was adverse events. Pancreatitis, cholangitis, bleeding and perforation were reported in 
3.9%, 1.4%, 3.1% and 3.9% of patients, respectively. A more recent retrospective review of 
multicentre data revealed adverse events in 13.2% of patients after SOCP, with cholangitis rates 
decreasing from 12.8% to 1% when prophylactic antibiotics were administered.95 In the raw data 
from the meta-analysis by Korrapati et al. (including 49 observational studies) adverse events 
after cholangioscopy applied in the treatment of stone disease ranged between 0% and 25%, with 
cholangitis being the most common.64 Pancreatitis was relatively rare likely due to the presence of 
a previous sphincterotomy in many cases. A more recent aggregate review and meta-analyses 
reported adverse event rates after cholangioscopy of between 6.1%-9.4%, and adverse event rates 
after pancreatoscopy between 0%-35%.65,74,81,96  
Only two previous studies report on adverse events associated with the addition of SOCP at the 
time of ERCP.97,98  Sethi et al. found an increase in the rate of adverse events from 2.9% to 7% 
when cholangioscopy was added to ERCP (OR 2.50; 95% CI [1.56-3.89]).97 A significant 
difference in rate, particularly in terms of cholangitis, was determined (0.2% to 1%), however, 
adverse event rates remained comparable for pancreatitis (1.3% vs. 2.2%). Their report was a 
single centre study including 3475 ERCP procedures and 402 SOCP and ‘mother-baby’ 
procedures and was based on data from a prospectively maintained database. Limitations 
included an inability to establish pre-determined definitions of adverse events and that data was 
dependent on endoscopist self-reporting (without subsequent validation). Hammerle et al., in a 
single centre comparison of 1918 ERCP procedures and 169 SOCP procedures, found an overall 
adverse event rate of 7.7% and rates for pancreatitis, cholangitis, bleeding and perforation of 
2.2%, 1.1%, 2.1% and 0.8%, respectively.98 After multivariate analysis, they found no increase in 
adverse events if SOCP was added to ERCP (OR 1.43, 95% CI [0.77–2.65]). The authors relied 
on data from patient charts and laboratory reports, and referral centre reporting of delayed adverse 
events. 
When considering the introduction of a new technology, associated cost, learning curve, clinical 
gain and adverse events need to be considered by the clinician. The main aim of study I was to 
define the clinical gain of SOCP when added to ERCP in a large patient sample. Study II was 
designed to describe the nationwide integration of SOCP and the extent to which adverse events 
are influenced when SOCP is added to ERCP. 
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2.5 ENDOSCOPIC STENTING 
 
The motivation for stenting in patients with malignant biliary strictures is twofold; on the one 
hand, it provides preoperative drainage as a ‘bridge-to-surgery’ in tumours deemed resectable but 
where there is a specific indication for drainage; on the other hand, it provides palliative drainage 
when tumours are irresectable or metastatic, or when patient functional reserve precludes curative 
surgery. Most patients presenting with malignant biliary obstruction are candidates for palliative 
stenting, with curative treatment being the exception.  
The treatment goal differs for patients undergoing preoperative vs. palliative drainage although 
minimising adverse events and the number of interventions is universal. The main aim of 
palliative drainage is relief of jaundice to improve quality of life (appetite, pruritis and general 
well-being) as part of end-of-life care. The treatment goal in palliative drainage is thus to achieve 
and maintain drainage of enough liver volume to allow for symptomatic control and to facilitate 
administration of oncological therapy. Preoperative drainage is a contentious issue and not 
universally advocated as infective perioperative complications are increased in such patients, 
demanding a risk vs. benefit calculation. The goal in the preoperative setting is to primarily drain 
the future liver remnant in selected patients only, mainly to limit perioperative complications.  
2.5.1 Approach to distal drainage  
 
Options for palliative distal drainage include surgical bypass (hepatico-, choledocho- and 
cholecystojejenostomy), ETP drainage, PTH drainage and more recently, endoscopic ultrasound-
guided drainage (EUS-GD). Due to easy endoscopic access to the distal biliary tract and success 
and morbidity rates of > 95% and < 5%, respectively, ETP stenting is the most common approach 
for palliative drainage in patients with obstructing distal cancer.23 Surgery is reserved for tumours 
deemed irresectable at the time of operative exploration and PTH drainage for cases of failed 
ERCP. Two meta-analyses of five available RCTs comparing surgery to ETP drainage 
consistently found surgery to provide longer-lasting relief of jaundice.99,100 Notably, findings in 
terms of rates of morbidity and mortality were contradictory between the aforementioned meta-
analyses. The analysis performed by Lima et al. highlighted the many biases involved and found 
lower procedure-related morbidity and 30-day mortality in patients treated with endoscopy.100 All 
five above-mentioned RCTs reported 30-day mortality in absolute numbers with a low risk of 
bias demonstrated. 
PTH drainage is often performed as a two-stage procedure, with initial percutaneous internal-
external catheter (PIEC) or external catheter (pigtail) placement, followed by stenting. Technical 
challenges to a transhepatic approach are encountered in patients with minimal biliary dilation, 
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ascites or multiple liver metastases. In practice, the decision between an ETP and PTH approach 
is often dependent on local expertise and accessibility. Combination approaches, either 
simultaneous or sequential, can also be employed. The first EUS-guided 
cholangiopancreatography was performed by Wiersema in 1996, soon followed by the first EUS-
GD procedure by creation of a choledochoduodenostomy.101,102 The role of EUS-GD is rapidly 
expanding to include creation of a hepaticogastrostomy as well as combination and antegrade 
biliary stenting techniques. 
The choice between PTH drainage and EUS-GD for salvage after failed ERCP depends on local 
expertise, and while PTH drainage is more widely available, there has been a recent rise in reports 
on the use of EUS-GD. The first published meta-analyses favour EUS-GD above a PTH approach 
as first choice after failed endoscopic stenting due to less complications and reinterventions, and 
guidelines advise accordingly.103–107 The use of EUS-GD as primary drainage approach ‘in lieu 
of’ ETP stenting in patients with distal malignant obstruction has been evaluated in 3 RCTs and a 
single meta-analysis.108–111 Similar findings in terms of technical- and therapeutic success rates 
and risk of stent occlusion were reported, but with a decreased risk of post-procedure pancreatitis 
after EUS-GD (RR 0.22, 95% CI [0.05-1.02]). In recent meta-analyses comparing EUS-GD with 
both ETP and PTH drainage, EUS-GD had equivalent technical and therapeutic success and total 
adverse events rates.112–114 Reports on EUS-GD are, however, mostly from selected highly skilled 
EUS operators and published technical success rates (44%-100%) and adverse event rates (3%-
34%) are difficult to replicate in wide clinical practice. 
2.5.2 Distal stenting - stent type  
 
When comparing SEMS to PS performance in the distal bile duct for palliative distal drainage, 
four previous meta-analyses and a recent fifth (including 1713 patients) found SEMS to have 
improved patency and decreased re-intervention rates, most notably 3-4 months after first stent 
placement.115–119 Cost appears to be similar (even in patients with a life expectancy of < 3 
months), while quality of life is better after SEMS placement.120,121 The first comparisons of 
cSEMS vs. uSEMS did not uniformly support the anticipated increased patency of cSEMS, likely 
as decreased ingrowth is balanced out by increased migration.122–124 More recent meta-analyses, 
with contrasting inclusion criteria and outcomes, have all failed to show clear superiority for 
cSEMS vs. uSEMS.125–128 Plastic stent use is considered in cases where imaging is yet to be 
completed and a management plan (curative vs. palliative) yet to be finalised, and in patients 
scheduled to undergo biliary radiofrequency ablation.129  
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2.5.3 Preoperative distal drainage 
 
Multiple meta-analyses have confirmed worse operative outcomes if preoperative drainage is 
employed in patients with distal malignant obstruction.130–132 Indications for preoperative 
drainage are limited to patients presenting with cholangitis or intense severe pruritis, to those that 
will undergo neo-adjuvant therapy and to those in which surgery is delayed.23,133 As with 
palliative distal stenting, evidence, consensus and guidelines suggest an endoscopic approach 
(lower seeding and recurrence risk) with SEMS placement (longer patency) as preferred 
options.16,23,134 The performance of uSEMS and cSEMS is similar.135 Plastic stent use might be 
prudent to limit artefact on cross sectional imaging (compromising future diagnostic certainty) 
when stricture nature has not yet been confirmed.131 
In summary, evidence is almost unanimously in support of endoscopic SEMS placement for 
drainage in distal malignant obstruction. The situation for patients with MHO is less clear. 
2.5.4 Hilar stenting 
 
Endoscopic retrograde cholangiopancreatography in patients with MHO is technically more 
challenging as it is pathophysiologically and anatomically more complex. Patients with MHO 
often require drainage of more than one obstructed area, and a lack of adequate drainage (from an 
isolated segment) at the same setting predisposes to cholangitis.136 The anatomical angles formed 
by the confluence of the left and right hepatic ducts begs for controlled and directed actions. 
However, the area of intervention is anatomically further away from the endoscopist, affording 
less maneuverability/pushability when compared to distal stenting. There is debate as to how 
much of the liver volume needs to be drained to achieve sufficient decompression after palliative 
drainage. There is evidence for 25%-30% representing adequate treatment, whereas,  particularly 
in B-C types III and IV, drainage of > 50% (requiring bilateral or bisectoral stents) is associated 
with improved survival.137,138 As lobar atrophy can be found in patients with MHO, computerised 
tomography or magnetic resonance imaging targeted drainage of functional volume may be more 
important than absolute liver volume drained.139,140 
2.5.5 Approach to hilar drainage 
 
The best surgical option for drainage of MHO is the segment III cholangiojejenostomy due to the 
high rates of morbidity (51%) and mortality (27%) associated with intra-operative transtumoural 
tube/stent placement, right sectoral duct bypass and palliative resection.141 Retrospective series 
report superior patency, a better quality of life and increased survival when surgical drainage is 
compared to both ETP and PTH drainage, but inclusion is marred by selection bias, with frail 
patients never reaching the operating room.142,143 Even in the absence of RCTs comparing surgery 
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with ETP/PTH approaches, non-operative treatment is considered the treatment of choice in most 
centres. Moreover, surgical drainage is often not possible in patients with extensive left-sided 
hepatic metastasis or atrophy, or when direct tumour spread or portal hypertension precludes safe 
open access to the left hepatic duct. 
Non-surgical options for hilar drainage include ETP drainage, PTH drainage and EUS-GD. An 
endoscopic approach is not always the approach of choice for MHO, unlike for distal malignant 
obstruction. There are five RCTsthat compare an ETP with a PTH approach in patients with 
MHO (Table 2).144–148 Three older studies are difficult to interpret due to inclusion of distal and 
hilar tumours, failure to control for stent type or evaluation in patients with gallbladder cancer 
only.144–146 The two more recent RCTs were both closed prematurely due to higher-than-expected 
mortality in the PTH group in one study, and slow accrual due to referring clinician bias in the 
other.147,148 Of 17 available retrospective studies, eight evaluated preoperative drainage and nine 
evaluated palliative drainage, making comparative analyses challenging.149–165 
The reviewed meta-analyses are somewhat heterogenous, with some restricted to patients 
undergoing preoperative drainage and others including patients undergoing preoperative and/or 
palliative drainage for both distal and hilar cancers.166–168 The two most recent meta-analyses that 
compared an ETP with a PTH approach in malignant biliary obstruction (both distal/hilar and 
preoperative/palliative) reported similar findings and comparable technical and therapeutic 
success, overall complications and mortality.167,168 Cholangitis and pancreatitis rates were higher 
after an ETP approach, while bleeding rate was increased after a PTH approach. The pooled 
analysis by Moole et al. in 2016 is the only publication that exclusively addresses palliative 
drainage of MHO, and included 546 patients.103 The author found higher odds for successful 
drainage after a PTH approach (pooled OR 2.53, 95% [CI 1.57–4.08]), with similar complications 
reported for both approaches.  
 
 21 




No. of patients 









No. of procedures 











 Definition (%) Definition (%) 













TB fall > 20% during 
initial admission 
ETP 81 † 


















B-C I 30 
B-C II 19 
B-C III 9 
B-C IV 1 
Not stated ETP 58 
PTH 75 
Decrease in TB > 20% 
of the preprocedure 
value 
ETP 42 † 










ETP 2.0 † 
PTH 3.7 † 





B-C II 44 





TB < 50% pretreatment 
value in 7 days 
ETP 41 † 





ETP 52 † 















B-C I 2 
B-C II 7 
B-C IIIa 41 
B-C IIIb 20 










Normal calibre bile ducts 
in future liver remnant 
on US and a decrease in 
TB of at least 20% at 




ETP 56 † 
PTH 4 † 
Single procedure: 
ETP 15 † 






















B-C II 39 
B-C III-IV 61 
NA NA 50% reduction (or 
improvement to ≤ 2.5 
mg/dL) in the TB level 













†Statistically significant, ††All suspected malignant strictures (excluded B-C I). ETP, Endoscopic transpapillary; PTH, percutaneous transhepatic; B-C, Bismuth-Corlette; TB, total bilirubin; US, ultrasound; NA, not applicable.  
 
22 
There are four available meta-analyses exclusively including patients undergoing preoperative 
drainage of MHO (with emphasis on perioperative complications).169–172 All four reported 
equivalent technical success for the two approaches but higher cholangitis and pancreatitis rates 
after an ETP approach, with the most recent reporting a higher bleeding rate after a PTH 
approach. Concern remains regarding the risk for later development of seeding metastases after a 
PTH approach, which is higher compared to an ETP approach (22.0% vs. 20.5%).173 Due to the 
limitations in evidence, guidelines currently support PTH drainage for palliative stenting of B-C 
types III and IV.133,174 
Despite equivalent technical and therapeutic success rates, and decreased rates of pancreatitis 
reported for both rescue and primary EUS-GD when compared to ETP drainage in patients with 
distal malignant obstruction, data on EUS-GD in MHO is limited.112 There are currently 88 
published cases with a reported technical success rate of 98% and a therapeutic success rate of 
77%.175 All of the reports are from specialised centres where procedures are performed by highly 
skilled operators. Besides the evident advantages in patients with altered anatomy (Roux-and-Y 
gastric bypass) and failed access (cannulation), the transluminal (gastro- or duodenohepatic) 
drainage established at the time of EUS-GD obviates the need for bridging of the stenosis. 
Although possible to overcome, a major disadvantage is limited access to the right liver. 
2.5.6 Hilar stenting – stent type 
 
In the palliative treatment of MHO, the performance of metal stents, in particular uSEMS, has 
consistently been better in RCTs and subsequent meta-analyses, due to a superior drainage rate, 
decreased early adverse events, longer survival, increased patency, and a resultant decreased cost 
compared to PS.116,176–178 Superior patency might reflect decreased blockage of segmental 
branches by the mesh network of uSEMS.179 In a recent large propensity score matched 
retrospective series, multiple PS use was inferior to single SEMS placement in terms of 
therapeutic success and cholangitis rates.180 As is the case with distal stenting, PS placement may 
still be indicated when treating indeterminate strictures or in patients scheduled to undergo biliary 
radiofrequency ablation.129 
2.5.7 Hilar stenting – extent of drainage  
 
Unilateral stenting achieves drainage in up to 97% of patients, and sustained attempts at achieving 
placement of bilateral stents can increase cholangitis and liver abscess rates due to retained 
contrast in undrained segments.178,181,182 Bilateral stent placement, on the other hand, is associated 
with improved cumulative patency and survival in retrospective studies, particularly in patients 
with CC.180,183 Reported technical success rates for bilateral stenting are contradictory and 
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evolving (ranging from 76.9% to 95.5%), most likely due to heterogeneity in endoscopist 
skill.181,184 A recent RCT found higher therapeutic success rates and lower reintervention rates 
after bilateral stenting in B-C III-IV types.184  
Two systematic reviews comparing uni- to bilateral stenting were published in 2013, with a third 
and fourth added more recently.116,185–187 The analysis by Ashat et al. included the two available 
RCTs and five retrospective studies, and found a lower reintervention rate for bilateral stenting, 
with equivalent rates for technical success, early- and late adverse events and stent malfunction 
.178,184,186 Meybodi et al. included 18 studies (10 retrospective and 8 prospective, of which two 
randomised) and reported a higher weighted pooled rate of technical success for unilateral 
stenting vs. bilateral stenting (97% vs. 89%, p=0.003), with equivalent functional success 
(p=0.481) and adverse events.187 A recent systematic review of reports comparing unilateral and 
bilateral drainage using an exclusively PTH approach found no differences in technical and 
therapeutic success, nor early or late adverse events.188 
If bilateral hilar stenting is employed, either a stent-in-stent (SIS) or side-by-side (SBS) 
configuration is possible, both with advantages and disadvantages.189 SIS deployment fits the 
innate anatomy of the biliary tree better, places less pressure on the surrounding bile duct wall 
and allows for stent additions, the main challenge being to get the wire through the mesh network 
of the already deployed stent. SBS deployment is technically more straightforward if bile duct 
dilatation allows enough space for two stents in parallel. The fear that the combined radial force 
exerted on the bile duct and portal structures can lead to choledochal perforation or portal vein 
thrombosis, has not been borne out in evidentiary reports. Evidence, in the form of retrospective 
series and a single RCT, suggests comparable technical and therapeutic success and adverse event 
rates.190,191 In practice, endoscopists should be able to employ both techniques as individual 
anatomy and tumour pathology require. 
In summary, continued improvements in instrumentation and technical proficiency ensures a 
constant flow of reports on bilateral and trisectoral SEMS placement in the hilum.  Current 
evidence suggests that treatment should be targeted based on pre-procedure non-invasive 
imaging, and the emphasis should be to attain drainage of at least 50% of liver volume (whether 
uni- or multisectoral, or uni- or bilateral).174 For B-C types II-IV, especially after bilateral 
upstream contrast opacification, this would most likely imply bilateral stent placement.192 In 
patients where a non-dominant or atrophic lobe was drained initially (or inadvertently opacified at 
the time of stenting), bilateral stenting becomes critical. 
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2.5.8 Hilar stenting - distal stent position 
 
Reports on both PS and SEMS placement above the sphincter of Oddi (suprapapillary) hold 
promise for decreasing the occurrence of pancreatitis and cholangitis, and prolonging time to 
recurrent obstruction due to the hypothesized decreased risk of enteric content gaining entry to the 
stent.193,194 The decreased risk for cholangitis has, however, not been replicated in subsequent 
reports.195 A recent large retrospective study revealed an equivalent adverse event rate and 
patency period, while endoscopic revision success rate was higher in patients with distal stent 
location in the duodenum (transpapillary).196 In the prevailing environment where 
multidisciplinary and multimodality treatment of MHO is increasing survival and the need for 
reintervention, deliberate suprapapillary placement of hilar stents is not currently supported by 
evidence. 
2.5.9 Preoperative hilar drainage 
 
A recent meta-analysis including 16 retrospective studies confirmed increased morbidity for 
preoperative drainage, with poor outcomes most obvious in patients with lower serum total 
bilirubin (TB) values.197 There is no consensus regarding indications for preoperative drainage in 
MHO. It has been suggested in scenarios associated with high postoperative liver failure rates, 
such as cholangitis or a predicted postoperative future liver remnant of < 30%-50%.133,198 As 
previously discussed, there is no definitive evidence to recommend an ETP or PTH approach for 
preoperative drainage in MHO. It is still unclear whether PS, PIEC, SEMS or nasobiliary 
catheters perform best in this setting, and guidelines refrain from suggesting SEMS due to a lack 
of available evidence.133,199 As is the case with distal malignant obstruction, plastic stents and 
catheters limit artefact if imaging is yet to be performed.200 
2.5.10 Adverse events after endoscopic stenting 
 
It is well established that routine sphincterotomy before biliary stent placement is not advocated.16 
However, little research has been conducted to elucidate the extent to which hilar stenting 
influences the risk for adverse events. Reknimitr et al., in an analysis of 61 patients undergoing 
hilar stenting, did not find an increased risk of pancreatitis but reported an increased cholangitis 
risk.201 The authors reported the rate for cholangitis for B-C I, B-C II and B-C III-IV at 4%, 10% 
and 58%, respectively. In more recent retrospective studies, cholangitis rates vary between 29%-
46%.202,203 Xia et al., in a 2019 retrospective review of 502 patients with MHO, reported a 
cholangitis rate of 22% after hilar stenting and identified PS use and B-C IV types as independent 
predictors for the development of cholangitis.204 The authors reported nine procedure-related 
deaths, of which five were due to cholangitis and subsequent septic shock. Results from RCTs on 
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unilateral vs. bilateral stenting are conflicting. In initial reports, patients had a significantly higher 
rate of cholangitis after attempted (but failed) bilateral drainage.181 The most recent RCT 
comparing uni- and bilateral stenting substantiated the idea that bilateral stenting affords limited 
protection against cholangitis As no diff in cholangitis rates between the two groups were found 
(4.7% vs. 9.1%, p=0.323).184 
2.5.11 Recurrent biliary obstruction  
 
Stent specific complications, such as obstruction and migration, are viewed in current literature as 
causes of recurrent biliary obstruction rather than adverse events. Recurrent biliary obstruction is 
defined as the recurrence of jaundice and/or cholangitis following stent insertion.23,205 Causes can 
be classified as non-tumour related (66%), such as migration, kinking, sludge formation and food 
impaction, or tumour related (34%), such as ingrowth or overgrowth.206 Non-occlusion 
cholangitis occurs when a temperature above 38°C is recorded for more than 24 hours in the 
presence of cholestasis but in the absence of dilated bile ducts or a confirmed cause for recurrent 
biliary obstruction.205 
Randomised trials report 6- and 12-month patency rates after distal stenting for malignant 
obstruction between 68%-78% and 32%-55%, respectively.118,207 Mean patency after hilar 
stenting using SEMS in retrospective studies vary between 201-546 days according to bilateral or 
unilateral stent placement and RCTs report patency rates at 6- and 12-months of 30% and 17% 
respectively.177,178,202,206 A prospective study found more durable stent patency after bilateral 
stenting, with B-C type not affecting patency on multivariate analysis.184 A retrospective review 
found lower hilar SEMS patency in patients with gallbladder carcinoma, after left-sided SEMS 
placement and in cases where preprocedural cholangitis was present.202 A meta-analysis of nine 
small observational studies on the use of biliary radiofrequency ablation hold promise for its 
future use, with a pooled weighted mean difference in stent patency of 50.6 days being 
determined.208 
The extent to which outcome is worse in patients drained for MHO compared to distal malignant 
obstruction is not well-defined. Furthermore, there is no consensus in terms of patients with MHO 
regarding the optimal approach to gaining biliary access, number of stents to be utilized and 
extent of drainage to be persued.133,174,192 This paucity in knowledge is particularly apparent 
regarding specific B-C locations in the biliary hilum. Study III aimed to investigate adverse 
events and patency rates after distal and hilar stenting in the different B-C locations of the biliary 
tree, while study IV was designed to compare ETP and PTH approaches and explore how 




3 RESEARCH AIMS 
 
The aims of this thesis are: 
 
 To determine the clinical value, both therapeutic and diagnostic, of SOCP when 
added to ERCP 
 
 To address the nationwide integration of SOCP and to determine to what extent 
adverse events are influenced when SOCP is added to ERCP 
 
 To compare adverse events and reintervention rates after endoscopic stenting for 
MHO to stenting for malignant distal obstruction 
 
 To compare outcomes after ETP stenting with outcomes after PTH stenting in the 





4 MATERIALS AND METHODS 
 
4.1 PAPER I 
 
Study design 
Study I was a retrospective review of all SOCP procedures performed between March 2007 and 
December 2014 at a tertiary high-volume endoscopy unit. 
Procedures 
All patients were discussed at a multidisciplinary team (MDT) meeting and, according to unit 
protocol, received prophylactic antibiotics but no NSAIDs prior to SOCP procedures. An 
endoscopic sphincterotomy was completed in all patients and procedures were performed using 
the first-generation SpyGlass system. Electrohydraulic lithotripsy was performed using a 1.9-Fr 
coaxial electrode (Olympus, Sweden) or a bipolar biliary probe (Northgate Technologies, USA). 
All PSC patients received brush cytology and flow-cytometry while SOCP-guided biopsies were 
obtained at the discretion of the endoscopist. For the visual diagnosis of malignant biliary 
strictures, the presence of dilated, tortuous or irregular vessels was noted and for the diagnosis of 
IPMN, previously defined criteria were used.209 
Determination of clinical utility 
Each SOCP procedure's therapeutic value and diagnostic yield was evaluated using a predefined 4 
graded scale as depicted in Table 3. A single independent reviewer assigned a grade to each 
procedure by reviewing the impact that treatment delivered at the time of the procedure had on 
patient management (therapeutic procedure), or the impact that information obtained at time of 
the procedure had on the final MDT decision (diagnostic procedure). In cases where it was 
difficult to ascertain the relative contribution that other treatment or diagnostic efforts lent to the 
final management plan, cases were graded as grade 2. Regarding the diagnostic value of SOCP in 
assessment of indeterminate strictures the following examples applied: grade 1 – SOCP in no way 
contributed to the diagnosis, grade 2 – SOCP provided contributory information to sway the 
diagnosis towards benign or malignant but definitive diagnosis remained elusive, grade 3 – SOCP 
provided confirmation of a previous diagnosis of benign or malignant, and grade 4 – SOCP 





Table 3. Grading scale to estimate the clinical value of single operator cholangiopancreatoscopy. 
 Clinical utility of a single operator cholangiopancreatoscopy procedure 
Grade Therapeutic value Diagnostic Yield  
1 No value No yield No significant 
clinical gain 2 Did not alter clinical course Did not impact clinical decision making 
3 Assisted subsequent disease management Impacted on clinical decision making Great clinical 
significance 
4 Solved the clinical problem requiring no 
further therapeutic actions 






Baseline physical status was defined according to the American Society of Anesthesiologists 
(ASA) classification system with: I – a normal healthy patient, II – mild systemic disease, III – 
severe systemic disease, and IV – systemic disease that is a constant threat to life. Complex 
cholelithiasis was defined as either ‘difficult to remove’ common bile duct stones or intrahepatic 
stones. ‘Difficult to remove’ common bile duct stones were defined as stones not removed by 
conventional means (sphincterotomy and balloon extraction) and indeterminate strictures as 
strictures where conventional means (brush cytology and flow-cytology) did not lead to a 
definitive diagnosis as benign or malignant. Adverse events were defined and graded according to 
the ASGE lexicon (Suppl. Table 1).45 
Statistical analyses  
Descriptive statistics were used to analyze results with frequencies (proportions and percentages), 
means (normally distributed data), medians (non-normally distributed data) and ranges reported. 
To explore risk factors for the occurrence of adverse events, subgroup analysis was performed 
considering the following risk factors: pancreatoscopy (vs. cholangioscopy) and a non-dilated 
pancreatic duct (vs. dilated pancreatic duct). 
4.2 THE GALLRIKS REGISTRY 
 
The GallRiks registry is the Swedish Registry for Gallstone Surgery and ERCP and was the 
source of data for studies II and III. It is a prospective population-based registry conceived in 
May 2005 by three Swedish Societies: the Swedish Surgical Society, the Swedish Society of 
Upper Abdominal Surgery and the Swedish Society of Laparoscopic Surgery. It has as its aim to 
record all endoscopic, laparoscopic and open interventions in the gallbladder and biliopancreatic 
ductal system. GallRiks uses an internet platform (www.ucr.uu.se/gallriks) for online data 
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registration and running cost is covered by the Swedish National Board of Health and Welfare 
(Socialstyrelsen). Its strengths lie in wide national participation and systematic validation. 
Coverage 
To assess participation, annual cross-referencing of the International Classification of Diseases 
(ICD) codes is performed between the Swedish National Inpatient Register and 
patients/procedures entered into GallRiks, and results are made public to stimulate ongoing 
engagement. Since its start in 2007, participation in the GallRiks registry has steadily increased 
from 75% of ERCP’s registered in 2007 to 87% registered in 2009. From 2009 onwards it is 
considered nationwide with more than 90% of all cholecystectomies and ERCP’s performed in 
Sweden currently registered in GallRiks.210 The registry includes procedures from all University 
Hospitals, county/district hospitals and most private units in Sweden. 
Validity 
The validity of a national registry encompasses two dimensions; namely, completeness and 
correctness. Regarding the construct of GallRiks, clinicians enter initial data including baseline 
patient characteristics, choice of intervention, indication, technical success and adverse events. 
During the first two years of GallRiks coming into use, entered variables were adjusted to 
maximise captured data while at the same time minimising participant effort, and so increasing 
compliance. The GallRiks board meets on an ongoing annual basis to adjust the dataset as 
needed. Outcomes at 30 days after the procedure are completed by an independent local non-
physician coordinator that compare registry data with local patient records. Independent external 
audit of the registry is furthermore carried out at 3-yearly intervals. Validation takes place 
through a random selection of 50 patients from a participating unit in whom data is correlated 
with medical records. The 30-day follow-up frequency after cholecystectomy and ERCP in 
GallRiks is 96% and 95% respectively.210 A 2018 report confirmed the increased adverse events 
seen in units with a more complete 30-day follow-up, underscoring the importance of participant 
diligence.210 External audit results are published annually on the website 
(http://www.ucr.uu.se/gallriks/index.php/arsrapporter) and discussed with GallRiks appointed 
surgeons and Heads of Department at each unit. For the GallRiks registry, a validity above 98% 
has been reported regarding completeness and correctness of data.211  
This national registry has a function not only in quality control but also in improved health care 
policies. Research questions where conduction of a RCT will be costly and extend over several 
years have successfully been addressed by GallRiks-based studies.212–215 
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4.3 PAPER II 
 
Study design  
Study II was a nationwide case-control study nested within the cohort of ERCP procedures, with- 
or without SOCP and registered in the GallRiks registry between January 2007 and December 
2012. 
Selection of patients  
Patients where cholangiopancreatoscopy was performed with the mother-baby system or where 
follow-up was incomplete, were excluded from the study. Only patients where 30-day follow-up 
was complete and where cholangiopancreatoscopy was performed with the single operator 











Figure 5. Endoscopic retrograde cholangiopancreatography (ERCP) and single operator 
cholangiopancreatoscopy (SOCP) procedures included in Study II 
Definitions 
Common indications for SOCP or ERCP were defined as common bile duct stones, obstructive 
jaundice or malignancy. Conventional ERCP was defined as ERCP without the addition of 
cholangiopancreatoscopy. Endoscopic retrograde cholangiopancreatography specific adverse 
events were defined according to the internationally accepted ASGE lexicon (Suppl. Table 1) and 
baseline physical status according to the ASA classification system.45 Intraprocedural adverse 
events were defined as any occurrence that led to premature termination of the procedure. 
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Postprocedural adverse events were defined as complications occurring in the first 30 days after 
the procedure and requiring medical or surgical intervention. 
Statistical analyses  
Descriptive statistics and graphical methods were used to describe data, with Pearson’s chi-
squared test used for comparisons in contingency tables. A p-value of ≤ 0.05 was deemed 
significant. For the analysis of the impact of SOCP on adverse events, ERCP-specific adverse 
events were analysed individually and grouped as intra- or postprocedural adverse events. 
Univariate and multivariate logistic regression was performed with the following hypothesized 
risk factors taken into account: age (> 71 years and ≤ 71 years (median)), sex (female or male), 
ASA classification (ASA I-II or ASA III-IV), urgent or elective, native or postsphincterotomy 
papilla, pancreatic duct cannulation (yes or no), indication (common or uncommon) and sedation 
method (conscious sedation, propofol or general anesthesia). The models were tested for effect 
modification and were finally assessed for the goodness of fit. Odds ratios (OR) with 95% 
confidence intervals (CI) were calculated. Lastly, a subgroup analysis was performed with 
stratification of SOCP procedures into bile duct or pancreatic duct investigations. 
4.4 PAPER III 
 
Study design  
Study III was a nationwide population-based cohort study including all patients undergoing 
ERCP for malignant biliary obstruction and prospectively entered in the GallRiks registry from 
January 2010 to December 2017. Date of death was determined by cross-referencing with the 
Swedish Central Death Register and patients were followed until December 2018.  
Selection of patients  
All patients that underwent ERCP and were entered into the GallRiks registry were considered for 
inclusion in the study (Figure 6). Endoscopic retrograde cholangiopancreatography procedures 
that were not index procedures and patients where the indication was for reasons other than 
malignant biliary obstruction according to histological/cytological confirmation, MDT decision or 
the ICD-10 coding system were excluded from further study. Likewise, patients were excluded if 
a stent could not be placed due to failed cannulation or unsuccessful bridging of the stricture with 
a guidewire (complete stenosis), or where a stent was placed but the position of the stricture or 
stent was unclear (missing data). Only patients that underwent stenting for confirmed malignant 
biliary obstruction were included for the analysis of adverse events. For determination and 
comparison of stent failure, patients that received a PS, a combination of PS and SEMS, or 
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Figure 6. Flowchart of included ERCP procedures in Study III.  




An index procedure was defined as the first ERCP procedure performed. Baseline physical status 
was defined according to the ASA classification system. Proximal stricture extent was used as 
reference point for grouping of strictures into distal or hilar strictures. A distal stricture was 
defined as located in the ampulla of Vater or common bile duct with the proximal extent situated 
distal to the junction of the cystic duct to the bile duct. A hilar stricture was defined as involving 
or located above the cystic duct common bile duct junction with proximal extent in the common, 
left or right hepatic ducts. Hilar strictures were further subdivided according to the modified B-C 
classification system and B-C I-II subtypes were grouped as extrahepatic strictures while B-C III-
IV were grouped as intrahepatic strictures.25 Total procedure time was defined as time from 
endoscope insertion to endoscope withdrawal. Adverse events were defined according to the 
ASGE lexicon and grouped as intraprocedural and 30-days postprocedural (Suppl. Table 1).45 
Stent failure/patency was defined as the time to the need for endoscopic reintervention regardless 
of the cause for recurrent obstruction and according to the Tokyo criteria for reporting on 
transpapillary stenting.205 The time point of recurrent biliary obstruction was defined as the point 
at which symptoms associated with obstruction necessitated reintervention. 
Statistical analyses  
Descriptive statistics were used for demographic and procedural data as well as adverse events. 
For within-group analyses, the Pearson's chi-squared test was used for the comparison of 
categorical data and the Student t-test for comparison of continuous data. For time to event 
statistical modelling, Kaplan-Meier analysis was employed. Endoscopic reintervention was 
considered a terminal event, whereas death or reaching the end of the study period with a 
functioning stent were treated as censored events. Cox proportional hazard models were utilised 
to calculate the risk for recurrent biliary obstruction according to age > 75 years (vs. < 75 years), 
male sex (vs. female sex), ASA class I-II (vs. ASA class I-II) and level of obstruction (hilar vs. 
distal), and hazard ratios (HR) and 95% CI were calculated. 
4.5 PAPER IV 
 
Study design  
Analysis of the large population-based cohort in study III functioned as a platform for design of 
study IV which was a retrospective comparison of palliative ETP and PTH drainage approaches 
performed for MHO at two specialised referral centres from January 2015 to June 2020. Patients 




Selection of patients  
Consecutive index palliative drainage procedures performed for irresectable MHO were included 
for study. Patients in whom both ETP and PTH procedures were planned, whether simultaneous 
or sequential, were excluded. For comparison of the duration of therapeutic success, patients with 
lymphoma were excluded due to their expected better prognosis compared to primary 
hepatobiliary and metastatic cancers. 
Procedures 
All patients were discussed at MDT meetings and both endoscopic and percutaneous procedures 
were performed under conscious sedation with general anesthesia available for selected cases. 
Diagnoses were based on a combination of imaging, tumour markers and cytological or 
histological confirmation. The index approach and stent characteristics were at the discretion of 
the endoscopist or interventional radiologist after discussion with the treating physician. When an 
intended approach failed to achieve technical success, the decision to reattempt the initial 
approach or the alternative approach was up to the treating physician. Serum TB values were 
repeated only for patients planned for palliative chemotherapy, and biliary radiofrequency 
ablation was not utilised at either of the two centres during the inclusion period. 
Data 
Data included baseline demographics, comorbidities, Eastern Cooperative Oncology Group 
(ECOG) functional performance score, serum values, diagnosis (including method of diagnosis), 
as well as modified B-C classification type.25 Stent characteristics included stent number, stent 
type (plastic vs. SEMS), stent position (internal PS/SEMS vs. PIEC) and the extent of intended 
drainage (unilateral, bilateral, trisectoral). For patients with B-C III strictures, unilateral stenting 
was described as ipsilateral or contralateral to segmental duct involvement. Procedure-related 
complications and severity grading according to the Modified Accordion Grading System 
(MAGS) for ETP and PTH approaches were documented and compared.216 
Technical success 
For ETP and PTH approaches access success (gaining entry to the bile duct), bridging success 
(guidewire crossing of stricture) and technical success (stent placement across stricture) were 
determined. For patients that crossed over from one drainage approach to another, the number of 
procedures before crossover were calculated. For patients that reached technical success, the 
number of procedures to stent placement was calculated for the successful approach, excluding 
procedures before crossover.  Additionally, for patients that reached technical success, stent 
characteristics and extent of drainage achieved (represented by the total number of segments 
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drained and the estimated percentage of liver volume drained (dichotomised into 33.3% 
increments)) were documented. The extent of drainage achieved was assessed by a single 
reviewer after each drainage procedure and formal volumetric analysis was not performed on all 
patients. 
Therapeutic success 
Biochemically confirmed therapeutic success (TB value ≤ 40 µmol/L) was documented and 
compared for ETP and PTH approaches. Assuming a linear decrease in TB from first stent 
placement, the time point of calculated therapeutic success was taken where the serum TB value 
first crossed the 40 µmol/L line. Time to therapeutic success was defined as the time between the 
time points of achieving technical success and calculated therapeutic success. Time to therapeutic 
success was compared for ETP and PTH approaches independently, per B-C type, and as a 
function of stent characteristics and extent of drainage achieved. The influence of stent 
characteristics and extent of drainage on achievement of therapeutic success was explored 
regardless of which approach was used. Failure of therapeutic success (first TB value of ≥ 40 
μmol/L) was documented and the duration of therapeutic success was compared for ETP and 
PTH approaches and per B-C type.  
Definitions 
Successful biliary access was defined as advancement of a catheter percutaneously or 
endoscopically into the bile duct, proximal and distal to the stricture, respectively. Successful 
bridging was defined as passage of a guidewire across the stricture. Technical success was 
defined as successful stent/PIEC placement across the stricture according to the Tokyo criteria for 
reporting on transpapillary stenting.205 Biochemically confirmed therapeutic success was defined 
as a TB value of ≤ 40 μmol/L. Time to therapeutic success was defined as the time between the 
time points of achieving technical success and calculated therapeutic success. Failure of 
therapeutic success was defined as recurrent biliary obstruction regardless of cause with a TB 
value of ≥ 40 μmol/L. Duration of therapeutic success was defined as the time between the time 
points of therapeutic success and failure of therapeutic success. Complications were classified as 
intraprocedural (from entering the preparation area to leaving the endoscopy/radiology room) and 
early (≤ 14 days) or late (> 14 days) postprocedural. Endoscopic biliary drainage complications 
were defined according to ESGE guidelines and PTH drainage complications were defined 
according to the Society of Interventional Radiology (SIR) guidelines (Suppl. Table 1).16,217 
Statistical analyses  
Categorical variables (expressed as percentages) were compared by the Chi-squared or Fisher’s 
exact test and continuous variables (expressed by means (SD) or median (IQR)) by means of the 
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two-samples t-test or Mann-Whitney U test. Within-group analyses were performed to explore 
outcomes for different B-C types and a p-value of ≤ 0.05 was regarded as significant. Multivariate 
logistic regression was performed to measure the influence of stent characteristics and extent of 
drainage achieved on eventual achievement of therapeutic success. For the analysis the following 
hypothesized risk factors were taken into account: B-C type (B-C I-IV), stent number (1 stent or > 
1 stent), stent type (plastic or SEMS), stent position (internal PS/SEMS or PIEC), extent of 
intended drainage (unilateral, bilateral, trisectoral), total number of segments drained 
(dichotomized into <3, 3-6 and >6) and estimated percentage of liver volume drained 
(dichotomised into 33.3% and 50% increments). Odds ratios with 95% CI were calculated. 
Kaplan-Meier analysis was used to assess duration of therapeutic success and restricted mean 
survival time analysis was used to compare duration of therapeutic success between approaches 
and B-C types to supply clinically applicable estimates. 
4.6 ETHICAL CONSIDERATIONS 
 
Study I and II was approved by the Regional Research Ethics Committee in Stockholm and study 
III by the Regional Research Ethics Committee in Umeå, Sweden. Since these studies were 
purely retrospective in nature, informed consent from included patients was not required by the 
Review Boards. For conduction of study IV, ethics approval was obtained from the Regional 
Ethics Review Boards at both participating centres, the University of Stellenbosch and the 
University of Cape Town, South Africa. As the academic database developed for registration of 
all patients with MHO in the Western Cape would function as a prospective registry in future, it 
was in addition registered at the Human Research Ethics Committee, University of Cape Town as 
such. Included participants in study IV were entered in a retrospective manner, and thus informed 
consent was waived. Permission to use patient records was obtained from the Provincial Health 
Research Committee of the Western Cape. All study protocols complied with the ethical 





5.1 PAPER I 
  
Over a 7.8-year period a total of 365 SOCP procedures were performed in 311 patients. In 71% of 
patients the bile duct was the main target of the procedure, in 24% the pancreatic duct, and in 5% 
both ducts. In 79.6% of cases the procedure could be performed in an outpatient setting. Patient 
demographics and indications for SOCP procedures are summarized in Table 4. Procedure time 
was a median of 99 min (range 50-275) and 15.9% of patients underwent a SOCP procedure for 
complex cholelithiasis, while 55.1% of patients underwent a SOCP procedure for indeterminate 
biliary stricture evaluation (non-PSC patient 32.6% and PSC patients 22.5%). 











Patients undergoing a single procedure  273 (88)  Complex cholelithiasis  58 (15.9) 
Patients undergoing multiple procedures  38 (12) 
Female sex  137 (44)  Indeterminate stricture (non‐PSC patient)  119 (32.6) 
Age (years)  64 (4‐94) 




     ASA II  186 (51)  Chronic pancreatitis (+/‐ lithotripsy)  20 (5.5) 
     ASA III  121 (33) 
     ASA IV  0 (0)  Miscellaneous  22 (6) 
ASA, American Society of Anesthesiologists; PSC, primary sclerosing cholangitis; IPMN, intraductal papillary mucinous neoplasm. 
Clinical utility  
Single operator cholangiopancreatoscopy was found to be of pivotal clinical importance (grade 4) 
in 19% of cases and of great clinical significance (grade 3) in 44% of cases, while the procedure 
did not affect clinical decision-making or alter clinical course (grade 1 and 2) in 37% of cases 
(Figure 7). The largest number of grade 2 procedures were due to an inability to definitively 
ascertain the relative contribution of the information provided by the SOCP procedure, in the 






Figure 7. The relative (%) 
distribution of therapeutic value 
and diagnostic yield as scored 





Figure 8 is a representation of the assigned grades grouped as grade 1–2 or grade 3–4, according 
to the indications for a SOCP procedure. SOCP was found to be of significant clinical value 
(grade 3-4) in 79% of procedures performed for the treatment of complex bile duct stones, 66% of 
procedures performed as part of work-up for cystic pancreatic lesions, 57% and 56% of 
procedures performed for the evaluation of indeterminate biliary strictures in non-PSC and PSC 











Figure 8. Representation of the assigned grades (grouped as grade 1–2 or grade 3–4) according 




Adverse events after single operator cholangiopancreatoscopy  
The overall adverse event rate was 16.2% with the majority (96.6%) graded as mild to moderate. 
Pancreatitis was the most common (7.9%) and the cause for the single postprocedural mortality. 
In this patient a simultaneous EUS-guided cystic pancreatic lesion puncture was performed 
together with the SOCP procedure and severe necrotizing pancreatitis ensued that ended with 
multi-organ failure and death on day 101 post procedure. We could not demonstrate a change in 
pancreatitis risk over time. When analysing specific risk factors for the occurrence of 
postprocedural adverse events, we found that pancreatoscopy was associated with an overall 
adverse event rate of 19.8% as compared to 9.6% for cholangioscopy. In the pancreatoscopy 
group we furthermore found a non-dilated main pancreatic duct in 9/17 pancreatitis cases (53%). 
5.2 PAPER II 
 
Over a 6-year period a total of 37456 ERCP procedures were registered in GallRiks with 66 
cholangiopancreatoscopy procedures performed with the mother-baby system and 408 with the 
single operator (SpyGlass) system (Figure 5). From 2007 onwards the number of SOCP 
procedures increased progressively from 16 in 2007, to 89 in both 2011 and 2012. An opposing 
decrease was seen in the number of mother-baby procedures (14 in 2007 to 6 in 2012). SOCP was 
utilised at 10 units in Sweden (mainly University Hospitals) with 69% of procedures performed at 











Figure 9. Single operator cholangiopancreatoscopy (SOCP) procedures per hospital during a 6-
year period. Hospital A is the Karolinska University Hospital. 
 
42 
Suspected or known common bile duct stones, obstructive jaundice and malignancy was the 
indication for intervention in 16.9%, 2.9% and 12.3% of SOCP procedures respectively while 
26.7% of procedures were performed in patients with PSC. Patients in the SOCP group were 
younger healthier males, undergoing more elective procedures under general anesthesia. SOCP 
procedures, when compared to conventional ERCP procedures, were associated with less native 
papillae (48.0% vs. 78.4%, p<0.0001), a higher cannulation rate (99.2% vs. 91.9% p<0.001), a 
lower rate of EPLBD or sphincterotomy (44.6% vs. 63.4%, p<0.001), more pancreatic duct 
interventions (31.4% vs. 23.3% p<0.001) and a lower rate of common bile duct stone clearance 
(58.2% vs.  71.6%, p=0.001). 
Adverse events 
Postprocedural adverse events, including pancreatitis and cholangitis, were more common in the 
SOCP group compared to the conventional ERCP group (19.1% vs. 14.0%, p=0.003, 7.4% vs. 
3.9%, p<0.001 and 4.4% vs. 2.7%, p=0.003 respectively). Postprocedural adverse events were 
higher in the early period compared to the later period (25.3% vs. 15.7 %; p=0.017). The increase 
in postprocedural adverse events seen when SOCP is added to conventional ERCP was present in 
the early period (25.3% vs. 13.4%, p<0.001) but disappeared in the later period (15.7% vs. 
14.5%, p=0.602). On univariate analysis, the risk of postprocedural adverse events, pancreatitis 
and cholangitis was increased for SOCP (Table 5). After adjustment, the risk for both 
intraprocedural and postprocedural adverse events were increased, while the risk for pancreatitis 
and cholangitis disappeared.  
Table 5. Odds ratios and 95% confidence intervals for the risk of adverse events among patients 
undergoing single operator cholangiopancreatoscopy (SOCP) compared with conventional 





OR  95% CI  OR  95% CI 
Intraprocedural  1.52  0.90 ‐ 2.40  2.25  1.31 ‐ 3.61 
Postprocedural  1.45  1.13 ‐ 1.85  1.35  1.04 ‐ 1.74 
Pancreatitis  1.98  1.33 ‐ 2.83  1.48  0.98 ‐ 2.15 
Cholangitis  1.67  1.00 ‐ 2.61  1.38  0.82 ‐ 2.18 
Bleeding  1.19  0.61 ‐ 2.07  1.82  0.93 ‐ 3.21 
Perforation  2.15  0.66 ‐ 5.10  1.66  0.51 ‐ 3.98 
SOCP, single operator cholangiopancreatoscopy; ERCP, endoscopic retrograde cholangiopancreatography; OR, odds ratio; CI, confidence 
interval. 
After stratification into procedures where bile or pancreatic duct cannulation was performed, 
there was an increased risk for intraprocedural adverse events after bile duct cannulation, even 
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after adjustment for confounders (Table 6). The increased risk for postprocedural adverse events 
and pancreatitis after pancreatic duct cannulation that was present on univariate analysis, 
disappeared after adjustment for confounders. 
Table 6. Odds ratios and 95% confidence intervals for the risk of adverse events among patients 
undergoing single operator cholangiopancreatoscopy (SOCP) compared with conventional 
endoscopic retrograde cholangiopancreatography (ERCP) stratified according to bile duct or 
pancreatic duct cannulation. 
Adverse events  Bile duct cannulation  Pancreatic duct cannulation 
Univariate  Multivariate  Univariate  Multivariate 
OR  95% CI  OR  95% CI  OR  95% CI  OR  95% CI 
Intraprocedural  2.05  1.05 – 3.59  3.01  1.52 – 5.36  1.25  0.49 – 2.62  1.77  0.68 – 3.83 
Postprocedural  1.34  0.97 – 1.82  1.29  0.92 – 1.76  1.58  1.04 – 2.35  1.40  0.91 – 2.09 
Pancreatitis  1.52  0.78 – 2.66  1.50  0.76 – 2.65  2.03  1.20 – 3.25  1.50  0.87 – 2.44 
Cholangitis  1.87  1.06 – 3.05  1.48  0.83 – 2.45  1.03  0.25 – 2.76  0.88  0.21 – 2.37 
Bleeding  1.22  0.52 – 2.41  1.69  0.71 – 3.40  1.23  0.37 – 2.95  2.25  0.67 – 5.71 
Perforation  2.05  0.34 – 6.52  1.51  0.25 – 4.89  2.65  0.43 – 8.66  2.68  0.43 – 8.83 
OR, odds ratio; CI, confidence interval. 
5.3 PAPER III 
 
Over a 7-year period a total of 58981 ERCP procedures were registered into GallRiks with 4623 
of these performed for stenting of malignant biliary obstruction (Figure 6). Seventy and a half 
percent of patients (n=3259) had a distal stricture and 29.5% a hilar stricture (n=1364), of which 











Figure 10. Flowchart indicating the position of strictures in Study III. B-C, Bismuth-Corlette. 
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Demographic details and adverse events  
Patients undergoing hilar stenting were more often female, younger and in a higher ASA class 
compared to patients undergoing distal stenting, while time from scope insertion to withdrawal 
was longer (Table 7). Hilar compared to distal stenting was associated with a higher total adverse 
event rate (19.2% vs. 14.2%, p<0.001) mostly attributable to increased postprocedural adverse 
events (17.2% vs. 12.0%, p<0.001). Both pancreatitis and cholangitis rates were increased after 
hilar stenting compared to distal stenting (6.6% vs. 4.0%, p<0.001 and 4.1% vs. 2.8%, p=0.024 
respectively). When comparing B-C I-II with B-C III-IV strictures, patients with more advanced 
B-C types were younger (68.8 years vs. 72.3 years, p<0.001) and procedure time was longer (65.9 
min vs. 47.6 min, p<0.001). Intraprocedural and postprocedural adverse events did not differ 
significantly between extrahepatic and intrahepatic stenting. 
Table 7. Demographic and procedural details and adverse events comparing endoscopic 
transpapillary stenting for distal versus hilar strictures as well as extrahepatic hilar strictures (B-C 

























Female  1670 (51.2)  750 (55.0)  0.020†   594 (56.9)  156 (48.7)  0.010† 
Male  1589 (48.8)  614 (45.0)  450 (43.1)  164 (51.3) 
Age (years)  72.5 (0.2)  71.4 (0.3)  0.005††  72.3 (0.4)  68.8 (0.7)  <0.001†† 
ASA I‐II  1938 (59.5)  638 (46.8)  <0.001†  503 (48.2)  135 (42.2)  0.060† 
ASA III‐IV  1321 (40.5)  726 (53.2)  541 (51.8)  185 (57.8) 
Procedure time (min)  36.9 (0.4)  51.9 (0.8)  <0.001††  47.6 (0.9)  65.9 (2.1)  <0.001†† 
Adverse Events 
Total  462 (14.2)  262 (19.2)  <0.001†  208 (19.9)  54 (16.9)  0.359† 
Intraprocedural  71 (2.2)  28 (2.1)  0.788†  23 (2.2)  5 (1.6)  0.480† 
     Bleeding requiring intervention  6 (0.2)  0 (0)  0.113†  0 (0)  0 (0)   
     Extravasation of contrast  37 (1.1)  12 (0.9)  0.439†  11 (1.1)  1 (0.3)  0.214† 
     Other intraprocedural  
     complication 
28 (0.9)  16 (1.2)  ‐  12 (1.1)  4 (1.3)  ‐ 
Postprocedural (30‐day)  391 (12.0)  234 (17.2)  <0.001†  185 (17.7)  49 (15.3)  0.318† 
     Pancreatitis  129 (4.0)  90 (6.6)  <0.001†  74 (7.1)  16 (5.0)  0.188† 
     Cholangitis  92 (2.8)  56 (4.1)  0.024†  44 (4.2)  12 (3.8)  0.714† 
     Perforation  9 (0.3)  3 (0.2)  0.732†  2 (0.2)  1 (0.3)  0.686† 
     Bleeding requiring intervention  26 (0.8)  13 (1.0)  0.599†  9 (0.9)  4 (1.3)  0.532† 
     Other postprocedural  
     complication 






Figure 11 is a representation of the need for endoscopic reintervention in months after hilar and 
distal single metal stent placement. At 6 months 56% of distally located stents required 
reintervention compared to 73% of hilar stents, while at 1 year 77% of distal stents and 89% of 
hilar stents required reintervention (p<0.001, p<0.001). 
The time to need for endoscopic reintervention according to different B-C types (B-C I-IV) is 
represented in Figure 12. Six months after single metal stent placement, reintervention was 
required in 56%, 70%, 76%, 90%, 87% and 86% of patients with distal and B-C I through to IV 
types respectively (p<0.001). 
 
 
Figure 11. Need for endoscopic 
reintervention in months after hilar 
and distal single metal stent 
placement. 
(Log-Rank: ChiSquare 47.07 
Prob>ChiSq <0.0001 






Figure 12. Need for endoscopic 
reintervention in months after 
single metal stent placement for the 
Bismuth-Corlette types (B-C I-IV). 
(Log-Rank: ChiSquare 58.85 
Prob>ChiSq <0.0001 







Multivariate analysis taking into account sex, age, ASA class and level of obstruction revealed 
male sex and hilar stricture location were significantly associated with the risk for reintervention. 
Patients with a hilar stricture had a three times higher risk of requiring reintervention after single 
hilar metal stent placement compared to distal metal stent placement (HR 3.47, 95% CI [2.01-
6.00], p<0.001) (Table 8). 








Hilar stricture  3.26 (1.89‐5.59)  <0.001  3.47 (2.01‐6.00)  <0.001 
Male sex  1.85 (1.12‐3.07)  0.017  1.97 (1.18‐3.27)  0.009 
Age > 75 years  0.98 (0.60‐1.62)  0.951  1.08 (0.65‐1.78)  0.775 
ASA III‐IV  1.05 (0.63‐1.73)  0.860  0.94 (0.56‐1.56)  0.804 
†Cox proportional hazard analysis 
5.4 PAPER IV 
 
Over a 5.5-year period, 293 patients underwent an index drainage procedure as palliation for 
MHO, 153 (52.2%) with an intended ETP approach and 140 (47.8%) with an intended PTH 
approach. Although patients in the two intended approach groups had a similar distribution of 
diagnoses and B-C types, patients in the ETP group more often had a confirmed tissue diagnosis. 
Eastern Cooperative Oncology Group performance score of 0, 3 and 4 were more common 
compared to the intended PTH group. Additionally, patients in the intended ETP group were 
older, had more chronic obstructive pulmonary disease, had a lower median serum alkaline 
phosphatase and a higher median serum haemoglobin level. 
A total of 263 patients (89.8%) reached technical success, 117 (44.5%) in the ETP group and 146 
(55.5%) in the PTH group. Comparison of the ETP and PTH technical success patient cohorts 
revealed similar diagnoses but more patients with B-C IV types in the ETP group. There were 
more patients with 0 or 3 comorbidities, more patients with chronic obstructive pulmonary 
disease and a higher median serum haemoglobin level in the ETP group. 
Thirty-four patients crossed over from an ETP to a PTH approach in order to reach technical 
success and 4 patients crossed over from a PTH to an ETP approach in order to reach technical 
success. Patients that crossed over from an ETP to a PTH approach were mostly B-C I types, and 
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when compared to patients that reached technical success via an intended PTH approach, 
crossover patients were older (Suppl. Tables 2-3). 
Technical success 
In total, 158 ETP approaches were attempted, 153 (96.8%) as the intended approach and 5 (3.2%) 
after crossover from the PTH group (Figure 13). A PTH approach was attempted in 179 patients, 
in 140 (78.2%) as the intended approach and in 39 (21.8%) after crossover from the ETP group. 
In the total technical success patient cohorts (intended approach and crossover) ETP vs. PTH 
access success was achieved in 83.5% and 97.2% respectively (p<0.001), bridging success in 
90.2% and 84.5% respectively (p=0.199) and technical success in 98.3% and 99.3% respectively 
(p=0.854). 
The number of procedures to reach technical success for the approach that ultimately achieved 
technical success were significantly less after an ETP approach, with 32.9% of patients requiring 
two procedures to achieve successful stent placement after a PTH approach (p=0.021). Bismuth-
Corlette subgroup analysis revealed that 100% of patients with B-C IIIa types reached technical 
success after a single procedure undergoing an ETP approach, compared to 55.2% of patients 
after a PTH approach (p<0.001). 
Figure 13. Access success, bridging success and technical success for endoscopic transpapillary 
and percutaneous transhepatic approaches. 
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Regarding number of procedures before crossover, patients that crossed from an ETP to a PTH 
approach had a median of two (range 1-3) procedures before crossover, while patients that 
crossed from a PTH to an ETP approach had a median of one (range 1-2) procedures before 
crossover (p=0.024). 
Comparison of stent characteristics at technical success revealed PIEC placement in 31.5% of 
patients after a PTH approach and similar rates of plastic stent/catheter and SEMS placement 
between ETP and PTH approaches. Patients in the ETP group, however, received more two stent 
and bilateral stent placements compared to patients in the PTH group (p=0.001, p<0.001). 
Bismuth-Corlette subgroup analysis revealed more bilateral and trisectoral stent placement after 
an ETP approach, most significant in B-C IIIa types (p<0.001).   
The extent of drainage achieved at technical success for ETP and PTH approaches revealed a 
similar total number of segments and estimated percentage of liver volume drained (p=0.968, 
p=0.209). B-C subgroup analysis indicated a trend towards a higher total number of segments and 
higher estimated percentage of liver volume drained in more advanced B-C types after an ETP 
approach, reaching statistical significance in B-C IIIa types (p=0.003, p=0.002). 
In the ETP group, SEMS were placed in 16 patients (13.7%) after initial technical success with a 
PS (stent exchange), at a median of 24 days (range 7-43). In the PTH group, SEMS were placed 
in 19 patients (13.0%) after initial technical success with a PIEC (internalisation), at a median of 
10 days (range 2-62) (p=0.875, p=0.851). Six patients in the ETP and PTH groups each required 
an additional SEMS placed to achieve therapeutic success. 
Therapeutic success 
Analysis of 146 patients in whom serum TB levels were serially performed revealed therapeutic 
success in 58 (81.7%) and 55 (73.3%) patients after an ETP and PTH approach respectively 
(p=0.242) (Table 9). Likewise, the median time to therapeutic success after ETP and PTH 
technical success was 30.5 days (range 1-345) and 28.0 days (range 1-83) respectively (p=0.577), 
with 54.9% of patients reaching therapeutic success regardless of approach within 29 days after 
successful stent placement (Figure 14). Similarly, on B-C subgroup analysis there was no 
difference between the two groups in the median time to achievement of therapeutic success and, 
due to small numbers, the influence of stent characteristics and extent of drainage achieved were 






Table 9. Successful achievement of therapeutic success following endoscopic transpapillary 
(n=71) versus percutaneous transhepatic (n=75) technical success for the different Bismuth-
















I  31/33 (93.9%)  28/39 (71.8%)  0.029  59/72 (81.9%) 
II  10/12 (83.3%)  14/20 (70.0%)  0.676  24/32 (75.0%) 
IIIa  9/14 (64.3%)  6/9 (66.7%)  1.000  15/23 (65.2%) 
IIIb  2/3 (66.7%)  5/5 (100%)  0.375  7/8 (87.5%) 
IV  6/9 (66.7%)  2/2 (100%)  1.000  8/11 (72.7%) 




Figure 14. Time to successful achievement of therapeutic success following endoscopic 
transpapillary (n=58) versus percutaneous transhepatic (n=55) technical success for all 




The association of stent characteristics on the achievement of therapeutic success regardless of 
approach is represented in Table 10. Within-group analysis revealed that SEMS vs. plastic 
stent/catheter placement and internal stenting (PS/SEMS) vs. PIEC use were positively associated 
with the achievement of therapeutic success (p<0.001, p<0.001). In patients with B-C IIIa and 
IIIb types bilateral or contralateral stent placement vs. ipsilateral placement was significantly 
associated with the achievement of therapeutic success (p=0.049, p=0.018). 
The association of the extent of drainage achieved on the achievement of therapeutic success is 
represented in Table 11. Within-group analysis revealed a trend towards more segments and a 
larger percentage of liver volume drained to be associated with the achievement of therapeutic 
success, but this was statistically significant only in patients with B-C IIIb types (p=0.018). 
On multivariate logistic regression modelling adjusted for B-C type, SEMS placement (vs. plastic 
stent/catheter placement) and internal stenting (vs. PIEC placement) had a higher odds for 
achievement of therapeutic success (OR 1.72, 95% CI [0.23-0.88], p=0.020 and OR 2.42, 95% CI 
[1.11-5.29], p=0.026). Regarding extent of drainage achieved, draining ≥ 50% of liver volume 
(vs. < 50%) had a higher odds for achievement of therapeutic success while draining ≥ 30% did 


































1  52/64 (81.3)  1.000  17/22 (77.3)  0.695  5/11 (45.5)  0.089  5/5 (100)  0.375  3/4 (75.0)  1.000  82/116 (70.7)  0.634 
2  7/8 (87.5)  6/8 (75.0)  10/12 (83.3)  2/3 (66.7)  5/7 (71.4)  30/38 (78.9) 
3  ‐  1/2 (50.0)  ‐  ‐  ‐  1/2 (50.0) 
Stent type  
Plastic  11/18 (61.1)  0.014  5/9 (55.6)  0.176  3/6 (50.0)  0.621  2/2 (100)  1.000  0/3 (0)  0.006  21/38 (55.3)  <0.001 




56/62 (90.3)  <0.001  23/28 (82.1)  0.039  14/20 (70.0)  0.269  7/8 (87.5)  ‐  8/11 (72.7)  ‐  108/129 (83.7)  <0.001 
PIEC  3/10 (30.0)  1/4 (25.0)  1/3 (33.3)  ‐  ‐  5/17 (29.4) 
Extent of intended drainage 
Unilateral  54/66 (81.8)  1.000  17/23 (30.4)  1.000  5/11 (45.5)  0.089  6/7 (85.7)  1.000  4/5 (80.0)  1.000  86/112 (76.8)  0.819 
Bilateral  5/6 (83.3)  7/9 (77.8)  10/12 (83.3)  1/1 (100)  4/6 (66.7)  27/34 (79.4) 
Trisectoral  ‐  ‐  ‐  ‐  ‐  ‐ 
Extent of intended drainage in cases of unilateral stenting for Bismuth‐Corlette IIIa and IIIb types 
Ipsilateral  NA  ‐  NA  ‐  2/7 (28.6)  0.049  0/1 (0)  0.018  NA  ‐  NA  ‐ 
Contralateral  NA  NA  3/4 (75.0)  6/6 (100)  NA  NA 






Table 11. The association of the total number of segments and estimated percentage of liver volume drained with the achievement of therapeutic success per 





























2  ‐  ‐  ‐  0.804  2/7 (28.6)  0.103  0/1 (0)  0.018  4/5 (80.0)  0.855  6/13 (46.2)  0.082 
3  ‐  5/6 (83.3)  3/4 (75.0)  ‐  2/3 (66.7)  10/13 (76.9) 
4  ‐  12/17 (70.6)  1/1 (100)  6/6 (100)  2/3 (66.6)  21/27 (77.8) 
5  ‐  ‐  9/11 (81.8)  1/1 (100)  ‐  10/12 (83.3) 
8  59/72 (81.6)  7/9 (77.8)  ‐    ‐  66/81 (81.5) 
Estimated percentage liver volume drained  
< 33%  ‐  ‐  5/6 (83.3)  0.804  5/11 (45.5)  0.141  0/1 (0)  0.018  4/5 (80.0)  0.382  14/23 (60.9)  0.084 
33%‐67%  ‐  7/9 (77.8)  2/2 (100)  1/1 (100)  2/2 (100)  71/86 (82.6) 






Duration of therapeutic success was significantly longer after an ETP approach compared to a 
PTH approach (p=0.009) (Figure 15a). After an ETP approach there was a 3-month gain in 
duration of therapeutic success over the first 400 days of follow-up adjusted for B-C type I vs. II-
IV (95% CI [26-160], p=0.006) (Figure 15b). 
Figure 15. a) Duration of therapeutic success following achievement of therapeutic success after 
an endoscopic transpapillary and percutaneous transhepatic approach. b) Duration of 
therapeutic success following achievement of therapeutic success after an endoscopic 
transpapillary and percutaneous transhepatic approach per Bismuth-Corlette type (B-C I vs. B-C 
II-IV). 
Duration of therapeutic success decreased progressively for B-C types I through to III, with 
duration shortest in B-C IIIa types (p=0.096) (Figure 16a). There were 7 patients with B-C IV 
types that were followed up, with only 1 failure of therapeutic success. After grouping into B-C I 
and B-C II-IV, a significant difference in duration of therapeutic success was observed between 
B-C I vs. B-C II-IV types (p=0.023) (Figure 16b). 
Figure 16. a) Duration of therapeutic success following achievement of therapeutic success per 
Bismuth-Corlette type. b) Duration of therapeutic success following achievement of therapeutic 






There were more intraprocedural penetrations (unintended penetration beyond the mucosa or 
duct) in the PTH group (4.8% vs. 0%, p=0.018) but similar severity grading between the two 
groups. Within 14 days from drainage, pancreatitis occurred in 9.4% of patients after an ETP 
approach while cholangitis rates were similar between the two groups (21.4% vs. 24.7%, 
p=0.530). There were more postprocedural deaths (MAGS grade 6) in the PTH group (15.8% vs. 
7%, p<0.001) of which most were sudden deaths where the exact cause of death could not be 
established definitively. Postprocedural complications > 14 days after drainage were similar 
between the two groups. 
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Supplementary Table 2. Demographic and clinical characteristics, diagnoses and Bismuth-Corlette 
classification of the endoscopic transpapillary and percutaneous transhepatic intended versus ‘crossover to’ 
















Female sex, n (%)  67 (59.3)  19 (57.6)  0.860  62 (55.4)  3 (75.0)  0.630 
Age, years, mean (SD)  60.7 (12.4)  64.4 (12.9)  0.169  58.0 (13.1)  67.5 (14.4)  0.142 
BMI, median (IQR)  26.3 (4.8)  22.9 (7.5)  0.112  26.3 (10.7)  ‐  0.338 
Number of comorbidities, n (%) 
0  51 (45.1)  13 (38.2)  0.103  36 (32.1)  2 (50.0)  0.876 
1  24 (21.2)  14 (41.2)  39 (34.8)  1 (25.0) 
2  26 (23.0)  7 (20.6)  29 (25.9)  1 (25.0) 
3  10 (8.8)  0 (0.0)  6 (5.4)  0 (0.0) 
4  2 (1.8)  0 (0.0)  2 (1.8)  0 (0.0) 
Comorbidities, n (%) 
Diabetes mellitis  21 (18.6)  6 (17.6)  0.902  14 (12.5)  0 (0.0)  1.000 
Hypertension  51 (45.1)  16 (47.1)  0.843  47 (42.0)  2 (50.0)  1.000 
COAD  9 (8.0)  1 (2.9)  0.454  2 (1.8)  0 (0.0)  1.000 
IHD  8 (7.1)  1 (2.9)  0.685  9 (8.0)  1 (25.0)  0.306 
HIV  7 (6.2)  4 (11.8)  0.279  9 (8.0)  0 (0.0)  1.000 
ECOG performance score, n (%) 
0  11 (11.5)  4 (13.3)  0.289  3 (3.0)  0 (0.0)  0.635 
1  50 (52.1)  13 (43.3)  59 (59.6)  2 (50.0) 
2  18 (18.8)  4 (13.3)  26 (26.3)  1 (25.0) 
3  13 (13.5)  9 (30.0)  11 (11.1)  1 (25.0) 
4  4 (4.2)  0 (0.0)  0 (0.0)  0 (0.0) 
Baseline serum values, median (IQR) 
Urea (mmol/L)  4.6 (3.1)  4.3 (2.9)  0.534  4.1 (3.0)  3.0 (5.7)  0.225 
Creatinine (µmol/L)  68.5 (33)  58.0 (31)  0.020  63.0 (30)  58.0 (30)  0.615 
Total bilirubin (µmol/L)  293.0 (220)  354.5 (181)  0.222  300.0 (219)  331.0 (257)  0.737 
Conjugated bilirubin (µmol/L)  237.0 (180)  262.0 (199)  0.256  258.0 (214)  286.0 (248)  0.831 
Aspartate transaminase (U/L)  147.0 (142)  128.0 (136)  0.429  159.0 (131)  186.0 (‐)  0.877 
Alanine transaminase (U/L)  136.0 (130)  108.0 (81)  0.150  119.5 (129)  60.5 (112)  0.134 
Alkaline phosphatase (U/L)  703.0 (730)  710.0 (488)  0.350  842.5 (876)  1171.0 (1675)  0.456 
Gamma‐glutamyl transferase (U/L)  791.0 (841)  555.5 (781)  0.115  575.0 (871)  997.0 (1404)  0.366 
Haemoglobin (g/dL)  11.5 (2.5)  10.7 (2.65)  0.259  10.9 (2.7)  10.0 (3.0)  0.410 
White Cell Count (109/L)  9.3 (4.4)  9.9 (6.4)  0.671  9.6 (5.2)  11.3 (20.1)  0.488 
Albumin (g/L)  31.0 (11)  30.5 (6)  0.749  31.0 (9)  30.0 (7)  0.347 
C‐reactive protein (mg/L)  42.0 (91.7)  ‐  0.101  50.0 (62.5)  ‐  0.307 





















Imaging and tumour markers   43 (38.1)  13 (38.2)  0.147  48 (42.9)  2 (50.0)  1.000 
Imaging and tissue sampling  47 (41.6)  9 (26.5)  31 (27.7)  1 (25.0) 
Imaging alone   23 (20.4)  12 (35.3)  33 (29.5)  1 (25.0) 
Diagnosis, n (%) 
Cholangiocarcinoma  80 (70.8)  20 (58.8)  0.467  68 (60.7)  3 (75.0)  1.000 
Gallbladder carcinoma  20 (17.7)  10 (29.4)  19 (17.0)  0 (0.0) 
Hepatocellular carcinoma  4 (3.5)  1 (2.9)  3 (2.7)  0 (0.0) 
Metasta c disease†  9 (8.0)  3 (8.8)  22 (19.6)  1 (25.0) 
Bismuth‐Corlette classification, n (%) 
I  45 (39.8)  23 (67.7)  0.024  43 (38.4)  1 (25.0)  0.347 
II  24 (21.2)  4 (11.8)  33 (29.5)  1 (25.0) 
IIIa  22 (19.5)  5 (14.7)  24 (21.4)  1 (25.0) 
IIIb  7 (6.2)  2 (5.9)  8 (7.1)  0 (0.0) 
IV  15 (13.3)  0 (0.0)  4 (3.6)  1 (25.0) 
†Including lymphoma and neuroendocrine tumour. BMI, body mass index; COAD, chronic obstructive airway disease; IHD, ischaemic heart 
disease; HIV, human immunodeficiency virus; ECOC, Eastern Cooperative Oncology Group; CA, cancer antigen. 
Supplementary Table 3. Demographic and clinical characteristics, diagnoses, and Bismuth-Corlette 
classification for endoscopic transpapillary and percutaneous transhepatic intended versus ‘crossover from’ 

















Female sex, n (%)  67 (59.3)  3 (75.0)  0.648  62 (55.4)  19 (57.6)  0.822 
Age, years, mean (SD)  60.7 (12.4)  67.5 (14.4)  0.285  58.0 (13.1)  64.4 (12.9)  0.010 
BMI, median (IQR)  26.3 (4.8)  ‐  0.222  26.3 (10.7)  22.9 (7.5)  0.815 
Number of comorbidities, n (%) 
0  51 (45.1)  2 (50.0)  1.000  36 (32.1)  13 (38.2)  0.657 
1  24 (21.2)  1 (25.0)  39 (34.8)  14 (41.2) 
2  26 (23.0)  1 (25.0)  29 (25.9)  7 (20.6) 
3  10 (8.8)  0 (0.0)  6 (5.4)  0 (0.0) 
4  2 (1.8)  0 (0.0)  2 (1.8)  0 (0.0) 
Comorbidities, n (%) 
Diabetes mellitis  21 (18.6)  0 (0.0)  1.000  14 (12.5)  6 (17.6)  0.569 
Hypertension  51 (45.1)  2 (50.0)  1.000  47 (42.0)  16 (47.1)  0.599 
COAD  9 (8.0)  0 (0.0)  1.000  2 (1.8)  1 (2.9)  0.551 
IHD  8 (7.1)  1 (25.0)  0.277  9 (8.0)  1 (2.9)  0.454 







0  11 (11.5)  0 (0.0)  0.893  3 (3.0)  4 (13.3)  0.007 
1  50 (52.1)  2 (50.0)  59 (59.6)  13 (43.3) 
2  18 (18.8)  1 (25.0)  26 (26.3)  4 (13.3) 
3  13 (13.5)  1 (25.0)  11 (11.1)  9 (30.0) 
4  4 (4.2)  0 (0.0)  0 (0.0)  0 (0.0) 
Baseline serum values, median (IQR) 
Urea (mmol/L)  4.6 (3.1)  3.0 (5.7)  0.210  4.1 (3.0)  4.3 (2.9)  0.869 
Creatinine (µmol/L)  68.5 (33)  58.0 (30)  0.363  63.0 (30)  58.0 (31)  0.089 
Total bilirubin (µmol/L)  293.0 (220)  331.0 (257)  0.916  300.0 (219)  354.5 (181)  0.490 
Conjugated bilirubin (µmol/L)  237.0 (180)  286.0 (248)  0.702  258.0 (214)  262.0 (199)  0.847 
Aspartate transaminase (U/L)  147.0 (142)  186.0 (‐)  1.000  159.0 (131)  128.0 (136)  0.356 
Alanine transaminase (U/L)  136.0 (130)  60.5 (112)  0.087  119.5 (129)  108.0 (81)  0.543 
Alkaline phosphatase (U/L)  703.0 (730)  1171.0 (1675)  0.384  842.5 (876)  710.0 (488)  0.039 
Gamma‐glutamyl transferase (U/L)  791.0 (841)  997.0 (1404)  0.449  575.0 (871)  555.5 (781)  0.529 
Haemoglobin (g/dL)  11.5 (2.5)  10.0 (3.0)  0.087  10.9 (2.7)  10.7 (2.65)  0.487 
White Cell Count (109/L)  9.3 (4.4)  11.3 (20.1)  0.410  9.6 (5.2)  9.9 (6.4)  0.801 
Albumin (g/L)  31.0 (11)  30.0 (7)  0.421  31.0 (9)  30.5 (6)  0.640 
C‐reactive protein (mg/L)  42.0 (91.7)  ‐  0.210  50.0 (62.5)  ‐  0.102 
CA 19‐9 (kU/L)  414 (2065)  4384 (‐)  0.111  719 (3229)  691 (1737)  0.636 
Method of diagnosis, n (%) 
Imaging and tumour markers   43 (38.1)  2 (50.0)  0.836  48 (42.9)  13 (38.2)  0.805 
Imaging and tissue sampling  47 (41.6)  1 (25.0)  31 (27.7)  9 (26.5) 
Imaging alone   23 (20.4)  1 (25.0)  33 (29.5)  12 (35.3) 
Diagnosis, n (%) 
Cholangiocarcinoma  80 (70.8)  3 (75.0)  0.504  68 (60.7)  20 (58.8)  0.230 
Gallbladder carcinoma  20 (17.7)  0 (0.0)  19 (17.0)  10 (29.4) 
Hepatocellular carcinoma  4 (3.5)  0 (0.0)  3 (2.7)  1 (2.9) 
Metastatic disease†  9 (8.0)  1 (25.0)  22 (19.6)  3 (8.8) 
Bismuth‐Corlette classification, n (%) 
I  45 (39.8)  1 (25.0)  0.920  43 (38.4)  23 (67.7)  0.044 
II  24 (21.2)  1 (25.0)  33 (29.5)  4 (11.8) 
IIIa  22 (19.5)  1 (25.0)  24 (21.4)  5 (14.7) 
IIIb  7 (6.2)  0 (0.0)  8 (7.1)  2 (5.9%) 









6.1 FINDINGS AND IMPLICATIONS 
6.1.1 Single operator cholangiopancreatoscopy 
 
Study I reported on 365 SOCP procedures from a tertiary centre and is, to our knowledge, the 
largest to date to assess the clinical value of adding SOCP to ERCP. Single operator 
cholangiopancreatoscopy had significant clinical value in 63% of patients. Reviewing its 
application in the biliopancreatic ductal system revealed that 71% were cholangioscopy 
procedures, 24% were pancreatoscopy procedures, while in 5% of cases both the bile and 
pancreatic ducts were targeted. In 21.4% of cases the SOCP procedure was enlisted in the 
treatment of benign (mostly stone) disease (biliary 15.9% vs. pancreatic 5.5%), while in 72.6% of 
cases it was utilised to assist in distinguishing benign from malignant disease (biliary 55.1% vs. 
pancreatic 17.5%). This utilisation of SOCP is in line with reports from most tertiary endoscopy 
units and likely reflects the spread of complex diseases challenging clinicians in practice.221 
Eighty percent of procedures were successfully performed in an outpatient setting, emphasising 
the minimally invasive nature of the procedure.  
Study II was an investigation of the nationwide integration of SOCP. Procedural adverse events in 
patients undergoing SOCP compared to conventional ERCP were higher. Similarly, overall, the 
incidence of postprocedural adverse events was 19.1% vs. 14.0% for the two procedures (SOCP 
vs. ERCP): pancreatitis (7.4% vs. 3.9%) and cholangitis (4.4% vs. 2.7%). These are important 
findings as previous studies from single centres and smaller patient samples reported lower 
adverse event rates when SOCP is added to ERCP (7.0%-7.7%).97,98  The overall increase in 
SOCP procedures and accompanying decrease in mother-baby procedures observed in this report 
reflects the ease of use of the single operator system. Its predominant use at a single University 
Hospital is in keeping with its application in complex hepatobiliary diseases, underscored by the 
fact that 27% of SOCP procedures were performed in patients with PSC and 17% were performed 
for stones not removed at previous ERCP.221  
Clinical utility of single operator cholangiopancreatoscopy  
In scrutinising the impact of SOCP for specific indications, it was found to have most value in the 
treatment of complex bile duct stones (79% grade 3-4). This is in keeping with previous reports of 
its effectiveness regarding eventual complete stone clearance (70%-94%) and becomes especially 
relevant to patients who are poor operative candidates.64,65 The long procedure time (mean of 99 
min) restricts is use and demonstrates a limitation of the procedure. 
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The second largest clinical value of adding SOCP to an ERCP procedure was found to be in the 
evaluation of cystic pancreatic lesions (66% grade 3-4). This correlates with recent reports that 
note that SOCP findings altered the extent of surgical resection in 62% of patients with IPMN.93 
Although dependent on frozen sections, intra-operative pancreatoscopy avoids ‘cannulation’ 
associated complications and may be a safer approach when employing SOCP to guide the extent 
of resection.92  
The clinical value of SOCP in the evaluation of indeterminate strictures graded as grades 3-4 
ranged from 56%-57% in patients without and with PSC, respectively. This illustrates the 
difficulty encountered when trying to differentiate malignant from benign strictures in the bile 
duct. Cytological confirmation of malignancy is possible in only 40%-60% of cases.37,40 The 
challenge in obtaining tissue for confirmatory diagnosis together with the increasing role of 
multimodality treatment, will likely drive clinicians to utilise SOCP in the evaluation of 
indeterminate strictures even in cases where the clinical yield is lower than for other indications. 
In study I, over half of patients (55%) underwent SOCP for indeterminate biliary stricture 
evaluation, demonstrating the aforementioned. 
In contrast to its value in the treatment of biliary stone disease, SOCP appeared to have the least 
impact in the small subgroup of patients who underwent SOCP for chronic pancreatitis with or 
without pancreatic stone lithotripsy. This subgroup was the only group where more patients were 
graded as grades 1-2 (55%) rather than grades 3-4 (45%). However, given the small sample size, 
caution must be exercised when interpreting this finding. In light of an increased adverse event 
rate associated with pancreatoscopy determined in both studies I and III, together with previously 
reported stone clearance rates from as low as 37% in the pancreatic duct, larger prospective 
studies are needed to assess the value of SOCP in patients with chronic pancreatitis.81 
Adverse events after single operator cholangiopancreatoscopy  
As SOCP is mainly utilised in patients with complex disorders (difficult stones and indeterminate 
strictures), multiple confounding factors can influence adverse event rates and multivariate 
analysis is of paramount importance to provide context. Possible risk factors for pancreatitis (e.g., 
female sex, younger age, sphincterotomy and EPLBD) and cholangitis (PSC and older age) could 
be statistically adjusted for in study II. On multivariate analysis, the risk for pancreatitis and 
cholangitis became less relevant, an increased risk for intraprocedural adverse events became 
evident and statistically significant, and the risk for postprocedural adverse events remained.  
Previous multicentre observational studies reported similar adverse event rates after SOCP and 
ERCP, while smaller comparative studies did not report an increased risk with the addition of 
SOCP (after adjusting for confounders).94,98 Results from study II assist in placing previous 
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reports of increased risk into perspective.97 Our results from a large and well-validated registry 
emphasise the caution that should be exercised when adding SOCP to an ERCP procedure and 
lend support to its use in high-volume centres. Comparing adverse events in patients undergoing 
SOCP in the first 3 years of study to the last 3 years of study suggested a definite learning curve, 
as the postprocedural adverse event rate after SOCP decreased from 25% to 16%.  
Adverse events after pancreatoscopy are less well defined due mainly to the retrospective nature 
of reports on small patient numbers.81,82,84,85 As wire passage into the pancreatic duct increases the 
risk for pancreatitis at the time of ERCP, the main concern would be the increased risk for 
pancreatitis particularly in patients with no previous history of pancreatitis or sphincterotomy. In 
our analysis of SOCP use in study I, pancreatoscopy was associated with an adverse event rate of 
20% (vs. cholangioscopy 9.6%). Although numbers were too small to analyse comprehensively, 
9/17 patients (53%) who developed pancreatitis after pancreatoscopy had a non-dilated pancreatic 
duct. In our exploration of adverse events after SOCP in study II, most confounders could be 
adjusted for, leading to the added risk for pancreatitis and cholangitis to diminish. After 
stratification into pancreatic and bile duct cannulation respectively, when the pancreatic duct was 
cannulated, the risks of postprocedural adverse events and pancreatitis were increased in the 
unadjusted analysis but this difference disappeared in the multivariate analysis. 
6.1.2 Hilar stenting 
 
Study III is, to our knowledge, the largest study to compare adverse events and reintervention 
rates after stenting of malignant biliary obstruction in different locations in the biliary tree. 
Adverse event rates when stenting takes place in the hilum compared to the distal biliary tree 
have not been well-defined in previous studies. The large sample size in study III allowed for 
increased power to detect statistically significant findings. Hilar stenting compared to distal 
stenting was associated with an increased total adverse event rate (19% vs. 14%), pancreatitis rate 
(6.6% vs. 4%) and cholangitis rate (4% vs. 3%).  
Study IV was a comparative cohort study of ETP and PTH palliative drainage procedures 
performed for MHO and is, to our knowledge, the largest comprehensive comparison of the two 
approaches to date. The strengths and weaknesses of the two approaches were highlighted for B-
C subgroups in terms of access, bridging and technical success, and achievement and duration of 
therapeutic success.  
Adverse events after hilar stenting 
Prior studies have not reported an increased risk of pancreatitis after hilar stenting and the high 
rates of pancreatitis observed in both studies III and IV (6.6% and 9.4%, respectively) may be 
 
64 
explained by the increased procedure time associated with hilar stenting (mean of 51.9 min). In 
addition, the non-dilated distal biliary tree, a well-known risk factor for pancreatitis, might 
contribute to increased rates. Our findings support current guidelines suggesting pancreatitis 
prophylaxis (rectal NSAIDs) for average-risk patients undergoing ERCP and emphasise this 
practice in patients undergoing hilar stenting.16,49 
Cholangitis rates after hilar stenting observed in study III (4.1%) reflect rates reported in RCTs 
(5%-17%) and confirm the increased risk when compared to distal stenting (2.8%).181,184 
Cholangitis rates reported in study IV after ETP and PTH drainage approaches (21.4% and 
24.7%, respectively) are more in line with reports from observational studies (30%-45%).203 
Interestingly, neither postprocedural adverse events nor cholangitis rates differed significantly 
between intrahepatic (B-C I-II) and extrahepatic (B-C III-IV) stenting in study III, contrasting 
with previous reports where more advanced B-C types predisposed to the development of 
cholangitis.201,204 The inability to control for mitigating and risk factors such as periprocedural 
antibiotics and undrained segments, may have confounded results in this smaller subgroup 
analysis.  
Hilar stent patency 
The definition and classification of recurrent biliary obstruction and the reasons for 
reintervention/stent failure are not well defined in current literature, making direct comparison 
difficult.23,205,206 In study III, 6-month patency rates for distal strictures compared to B-C I 
through to IV types were 44%, 30%, 24%, 10%, 12% and 14%, respectively. Reported 6-month 
patency rates for stenting of distal and hilar strictures in RCTs are 68%-78% and 25%-35%, 
respectively.118,177,178,207 Study III is the first to describe triple the risk for requiring reintervention 
in patients receiving a single SEMS for MHO compared to those receiving a SEMS for distal 
malignant obstruction. The innate anatomy of the biliary tree allows for more proximal stent 
overlap when distal stenting is performed. High reintervention rates in hilar compared to distal 
strictures might be partly explained by tumour progression and resultant non-occlusive stent 
failure (with- or without cholangitis), where reintervention is performed for undrained segments 
even though an adequate decrease in bilirubin has been established. It is important to note that our 
results reflect the need for reintervention in the population at large.  
Our finding of worsening patency in more advanced B-C types is in contrast to previous studies 
where B-C type was not associated with decreased patency.184 Patency was lowest for B-C IIIa 
types in both studies III and IV, questioning previous reports where left-sided SEMS placement 
predicted lower patency.202 This finding is most likely to be the effect of proximal disease 
progression around the short right hepatic duct, resulting in occlusion of segments that may be 
colonized, and requiring additional intervention.  
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Stent type and extent of drainage in the hilum 
Results from study IV support the superiority of uSEMS for drainage in MHO.116 The finding that 
B-C III types achieved therapeutic success more readily after bilateral stent placement 
substantiates bilateral drainage for more advanced B-C types. This topic is still under debate in 
current literature.186,187,191 Our finding that B-C III types achieved therapeutic success more 
readily after bilateral or contralateral vs. ipsilateral stent placement merits further discussion. 
Based on functional volumes of liver segments, drainage of > 50% of liver volume requires right-
sided or bilateral stenting in B-C II and IIIb types, and bilateral stenting in B-C IIIa and IV 
types.20 The short right hepatic duct is predisposed to sectoral duct involvement (B-C IIIa and IV) 
and a single right-sided stent in this scenario will unlikely achieve and maintain drainage of > 
50% of liver volume. 
Approach when stenting the hilum 
Study IV is the first to deconstruct access, bridging and technical success for ETP and PTH 
approaches, highlighting the strengths of each. An ETP compared to a PTH approach had inferior 
access success but superior bridging success, while technical success was similar. Most patients 
who crossed over from an ETP to a PTH approach did so after unsuccessful access (failed 
cannulation) and more procedures were required for eventual technical success via a PTH 
approach due to repeated attempts at bridging. Previous studies have not reported on reason for 
crossover or number of procedures required to reach technical success. 
Study IV was also the first to compare stent characteristics and extent of drainage between ETP 
and PTH approaches at the time of technical success. One of the advantages of an ETP approach 
is the potential to place multiple stents from one access point. Results from study IV revealed 
more two stent and bilateral stent placement after an ETP approach in advanced B-C types, which 
resulted in more segments and a larger percentage of liver drained. This did not have an impact 
on achievement of therapeutic success or time to therapeutic success, which was similar between 
the two approaches, but likely contributed to the superior duration of therapeutic success that was 
found after an ETP compared to a PTH approach. The 2016 meta-analysis by Moole et al. (the 
only to specifically compare palliative ETP with PTH drainage of MHO) included 2 RCTs and 7 
retrospective studies (546 patients).103 Our results, with equivalent therapeutic success for ETP 
and PTH approaches, challenge their finding of superior successful drainage after a PTH 
approach in advanced B-C types. Results from study IV question the dogma that a PTH approach 
should be used in advanced B-C types.133,201 
In study IV, B-C IIIa patients were more likely to receive bilateral stents and B-C IIIb patients 
were more likely to receive contralateral stents after an ETP approach. Liu et al., in a 
 
66 
retrospective analysis of 446 patients undergoing unilateral PS placement via a PTH approach 
found entry via the left lobe (compared to the right) associated with higher technical and 
therapeutic success, and decreased adverse events compared to a right-sided puncture.222 It may 
be that, after MDT discussion, if a decision is made to prioritise right-sided drainage, an ETP 
approach should be pursued first. If left-sided drainage is prioritised, a PTH approach should be 
pursued first. Future studies should continue to explore outcome differences for ETP and PTH 
approaches for advanced B-C types. 
Two recent meta-analyses reported similar overall complication and mortality rates, with 
pancreatitis and cholangitis rates higher after an ETP approach and bleeding rate increased after a 
PTH approach.167,168 Theoretically, unsuccessful access (failed cannulation) after an ETP 
approach predisposes to pancreatitis, whereas unsuccessful bridging after a PTH approach allows 
for placement of an external catheter (pigtail) and so protecting against cholangitis. Study IV 
confirmed more patients developed pancreatitis after an ETP approach, mostly of MAGS grade 1-
3, with a single pancreatitis-associated death (MAGS grade 6). Cholangitis rates between the two 
approaches were similar, likely due to more double/bilateral stent placement after ETP drainage. 
A recent RCT was prematurely closed after accrual of 54 patients due to a higher-than-expected 
mortality in the PTH approach group compared to the ETP group (41% vs. 11%) and, although 
not designed to compare survival, our study found more sudden deaths after a PTH approach 
(15.8% vs. 6.0%).147 
Comparative patency duration has not been extensively explored for ETP and PTH approaches. In 
prospective studies a PTH approach appeared superior, although not statistically significant.144,146 
In retrospective reports earlier studies favoured a PTH approach, while more recent comparisons 
found equivalence or superiority for an ETP approach.150,151,154,161 The longer duration of 
therapeutic success resulting in a gain of 3 months after an ETP approach seen in study IV is 
likely secondary to more bilateral stent placements and a larger volume of liver drained in 
especially advanced B-C types, as such safeguarding against future symptomatic recurrent 
obstruction. 
As the goals for preoperative and palliative drainage differ, the first aiming to drain the future 
liver remnant to limit perioperative complications and the second to drain enough functional liver 
volume to afford symptomatic relief or administer oncological therapy, comparative analyses are 
challenging. Two recent meta-analyses, including distal and hilar malignant obstruction in 
patients undergoing both preoperative and palliative drainage, reported similar technical and 
therapeutic success rates, overall complications and 30-day mortality for ETP and PTH 
approaches.167,168 The equivalence in technical success, therapeutic success and time to 
therapeutic success after ETP and PTH approaches found in study IV are in accordance with 
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these reports and again corroborate the philosophy that the two approaches are complementary 
rather than competitive. 
6.2 METHODOLOGICAL ASPECTS 
 
6.2.1 Paper I 
 
In the absence of an available system to assess the impact on patient management when SOCP is 
added to ERCP, the grading scale used in study I had to be developed anew. To ensure content 
validity, the grading scale had to be: 
1. Complex enough to measure all aspects of SOCP clinical value to allow differentiation 
between therapeutic and diagnostic intent.  
2. Practical and simple enough to be applied to a large number of procedures (n=365).  
It should be noted that the grading scale could not be correlated with previous scales, due to a 
lack of previously published scales. Criterion validity could not be calculated, and final validation 
will depend on future studies. 
The single reviewer used in study I was not involved in the clinical care of included patients, but 
the absence of more than one reviewer meant that reproducibility (interobserver variation) could 
not be calculated. Repeatability (intra-observer reliability) was maximized by defining examples 
in each grade (therapeutic vs. diagnostic). In cases where it was difficult to ascertain the relative 
contribution that other treatment or diagnostic efforts lent to the final management plan, cases 
were graded as grade 2. To further minimise bias, the reviewer decision as to final grading of 
diagnostic value was measured utilising the final MDT meeting decision, with the benefit of 
extensive expert input.  
The observer bias introduced when the endoscopists had access to all relevant clinical information 
at the time of visual assessment of biliary strictures or IPMN lesions, risks overestimation of the 
clinical value of SOCP. It is difficult from an ethical point of view to argue for withholding 
relevant information from the endoscopist. More importantly, incorporating clinical information 
(history, examination, serum markers and imaging) as the diagnostic process progresses (as new 
information becomes available), reflects everyday clinical practice. 
Inherent in studies attempting to assess diagnostic accuracy or impact on management is the 
absence of the gold standard of diagnosis (histology of the resected specimen) in strictures 
diagnosed as benign. Under these circumstances the clinical course can be used as a substitute, 
and due to the retrospective nature of the current study, this benefit could be utilised. 
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6.2.2 The GallRiks Registry 
 
Study II and III utilised prospective data from the nationwide Swedish Registry for Gallstone 
Surgery and ERCP (GallRiks). The main strength of both studies lies in the large sample sizes 
available for inclusion and comparison, minimising random errors and the effect of chance, and 
increasing statistical power of the studies. 
An advantage of the registry, when reporting on both SOCP and ERCP associated adverse events, 
is that since its conception adverse events have been defined according to internationally accepted 
criteria.45 This ensures reporting conformity and allows for comparison with previous reports. The 
population-based registry has nationwide participation (> 90% of hospitals in Sweden) thus 
minimising selection bias and increasing applicability to the population at large (high external 
validity). Selection bias is, however, inherent in self-reported registries where clinicians might be 
reluctant to declare undesirable outcomes. In the Gallriks registry this risk is minimised by the 
capturing and reviewing of 30-day adverse events by an independent non-physician coordinator. 
The 30-day follow-up frequency for GallRiks after cholecystectomy and ERCP is 96% and 95% 
respectively.210 
Population-based registry studies reflect what takes place at the bedside (high external validity) 
but internal validity becomes vulnerable due to the presence of unaccounted confounders.223 All 
possible variables that increase pancreatitis risk could not be accounted for (such as sphincter of 
Oddi dysfunction, a non-dilated bile duct and normal preprocedural liver function tests). 
Likewise, known factors that increase cholangitis risk (incomplete drainage in hilar obstruction) 
and bleeding risk (anticoagulant and antiplatelet use) could not be adjusted for. In both studies I 
and II, data on the use of known mitigating factors for pancreatitis (NSAIDs) and cholangitis 
(prophylactic antibiotics) was not available from the start of participant inclusion. In study III, 
important possible confounders regarding hilar stenting such as stricture number and length, the 
number of segments obstructed and subsequently drained, the volume of liver drained and the 
reasons for reintervention were not known, making definitive conclusions and comprehensive 
multivariate analysis problematic.  
Coordinator review and regular external auditing of adverse event documentation allowed for 
minimal missing data in study II (2.7%). There might be a concern regarding missing data in 
study III (34.3%) regarding stricture location and stent position. This was, however, a result of an 
inability to definitively classify stricture/stent position from the images captured in GallRiks, in 
which case patients were excluded.  
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6.2.3 Paper II 
 
Study II was a representation of the nationwide integration of SOCP, including data from 10 
Swedish centres, but there might be a concern that 69% of procedures were performed at a single 
high-volume University Hospital. On subgroup analysis and comparison there was, however, no 
difference in adverse events between this centre and the other units included in the study. 
National coverage of the registry between 2007 and 2009 saw an increase in participation from 
73% to 90%. The increase in participation was mostly due to the addition of regions and not due 
to increased participation in units already making use of the registry. With reference to analysis of 
adverse events after ERCP it should be noted that completeness for GallRiks participating units 
during this time period varied between 97.2% and 98.2%.211 
Both studies I and II included SOCP procedures performed with the first-generation SOCP 
system in use from 2007 to 2015. The digitalized second-generation system offers improved 
image quality and thus clinical value might be underestimated and adverse events overestimated 
when results from the current data is extrapolated to its future use. 
6.2.4 Paper III 
 
There might be concern for the different pathological processes and prognoses that are involved 
in distal and MHO. However, the focus in both studies III and IV was on anatomical and 
technical aspects of transpapillary stenting for malignant biliary disease such as approach, 
stricture and stent location, stent characteristics and patency. Because of differences in tumour 
biology regarding progression (ingrowth/overgrowth) and response to oncological therapy, 
survival was not addressed in either of the reports. Survival in patients with especially MHO is, 
however, limited.44 Once a diagnosis of irresectable hilar malignancy is made, the main treatment 
goal is symptomatic relief with/without the administration of oncological therapy, with survival 
following thereafter. 
The definition of a distal stricture used in study III (originating in the common bile duct below the 
cystic duct junction) does not consider the variability in cystic duct anatomy and can lead to 
misclassification of distal strictures as B-C I strictures and vice versa. The Asia Pacific consensus 
meeting in 2020 defined a distal stricture as an abnormal narrowing of the distal half of the 
extrahepatic bile duct and this definition will allow for consistency in future studies.23 
To enable comparison of the need for reintervention in study III and to limit confounders, we 
included only patients in whom a single metal stent was placed. The superiority of metal over 
plastic stents regarding patency for both distal and hilar malignant strictures has already been 
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proven and was not the objective of this study.116,119 We did not distinguish between the use of 
uSEMS or cSEMS in the current study as there is a lack of collaborating evidence showing a 
significant difference in outcomes between these two stent types for distal strictures.128 Both stent 
types are predisposed to recurrent biliary obstruction albeit via different pathways (cSEMS 
migration and overgrowth, uSEMS ingrowth). The use of metal stents in the hepatic hilum has 
been restricted to uSEMS to prevent blockage of secondary intrahepatic biliary radicles.133,179 A 
single stent establishes 100% drainage in distal and B-C I malignant strictures, while two stents is 
required in the hilum to drain more than 50% of the liver in more advanced B-C types (B-C IIIa 
and IV). There is ongoing robust debate as to the number of stents to be placed to achieve the 
treatment goal (safe resection, adequate symptom relief or administration of oncological 
therapy).186,187   
Matching of the GallRiks registry with the Swedish Central Death Register allowed for complete 
mortality data in patients stented for malignant biliary obstruction. The registry does not, 
however, account for indications for reintervention (stent factors, tumour factors or non-occlusion 
stent failure/cholangitis) and thus the reason for the much higher reintervention rate after hilar 
stenting could not be explored further. The registry furthermore only account for endoscopic 
interventions and operative, percutaneous, EUS-guided and oncological interventions are not 
represented. This underestimates the number of stent failures, especially for advanced B-C types. 
An important statistical limitation of the study also warrant consideration. Reintervention rates 
were calculated from retrospective data in contrast to patency duration calculated in a prospective 
manner. Death without re-intervention was treated as a censored event, but actual stent patency at 
the time of death could not be confirmed, and random censoring and an occluded stent at time of 
death could not be excluded (underestimating stent failure).  
The study has simplified and does not cover the whole spectrum of hilar stenting, having 
excluded patients treated with plastic or multiple stents and percutaneous or EUS-guided stents. 
Registries such as GallRiks, designed for ERCP and not specifically for hilar strictures, lack 
granular information on key variables, precluding in-depth analyses of important unanswered 
questions. However, the RCTs that have generated strong evidence regarding numerous issues 
concerning distal stenting, cannot be replicated in MHO.147,148 Despite the inherent drawbacks 
encountered when a registry is used retrospectively, and due the challenges posed by selecting a 
prospective randomised study design in many instances, combining these two methodologies in 
future can draw on the strengths of each (as evidenced in previous publications).224,225 Analyses of 
large population-based cohorts can be a platform for studies creating more robust data and the 
challenges encountered in study III could inspire the design of study IV. 
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6.2.5 Paper IV 
 
The use of classification systems, definitions and grading scales allows for standardization and 
easy comparison between reports. The B-C classification, definition of therapeutic success and 
MAGS grading system used in study IV posed specific challenges but were chosen for specific 
reasons. 
The B-C classification system was developed to guide the operating surgeon but has limitations 
when applied by the endoscopist or interventional radiologist.  
1. It indicates hepatic duct (common, left and right) involvement but disregards strictures 
stretching beyond sectoral ducts and does not take into account the 40% of anatomical variants 
where aberrant intrahepatic drainage is present.  
2. It does not account for functional liver volume proximal to strictures, whether healthy or 
atrophied, which is essential when planning drainage in more advanced stricture types. 
3. It fails to standardise the definition of a hilar or sectoral block which can be dependent on the 
force of contrast injection at the time of intervention.  
An ideal classification system to describe and guide hilar drainage is still lacking but should aim 
to reflect the functional state of the proximal liver parenchyma in addition to ductal topography. 
The definition of therapeutic success (TB value of ≤ 40 µmol/L) is based on previous publications 
where populations are undergoing drainage mostly as a bridge-to-surgery.152,155 It is less well 
suited as surrogate for the treatment goal in patients with irresectable or metastatic MHO where 
two groups are identified: those where TB values need to normalize before commencement of 
palliative oncological therapy and those with advanced disease where purely symptomatic relief 
is pursued. In accordance with end-of-life treatment goals, patients in study IV were not 
biochemically followed up beyond symptom resolution if symptomatic relief was the only 
intended outcome.44 
As additional access to the biliary tract is allowed endoscopically, percutaneously, and recently 
via EUS, definition and grading systems for complications applicable across all access 
approaches are lacking. Internationally recognised definitions were chosen for endoscopic and 
radiological complications respectively (Suppl. Table 1).16,217,218 An ideal grading system should 
be practical, easily clinically applied, general enough to reach across specialties and yet allow for 
a relatively detailed and accurate description of most eventualities. The Clavien classification 
system for post-surgical complications introduced the principle of grading according to the 
amount of effort required to reverse or manage a complication and was later modified by Dindo 
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(Clavien-Dindo) and Martin et al. (Memorial Sloan Kettering grading system).226–228 The 
Accordion grading system was developed as an adaptation of previous classifications to be more 
universally applicable to large and complex studies and was the system chosen for this study, 
allowing for applicability across different biliary approaches.219 
The retrospective nature of study IV meant that there was no control for random and institutional 
bias, e.g., selection of patients, biliary approach and stent type and number. Inclusion of patients 
from two centres with high-volume endoscopy and interventional radiology units (with 
independent functioning) mitigates this to some extent. Volumetric assessment was not performed 
on all patients and patients with no further interventions could not be accounted for. However, as 
the early closure of two recent RCTs demonstrates, comparison of ETP and PTH approaches is 
not easily performed prospectively.147,148 This is mostly due to divergent institutional expertise 
and availability and/or clinician bias towards a specific approach. Many confounders that need to 
be considered complicate the construction of practical inclusion and exclusion criteria. Future 
studies will have to depend on large multi-institutional registries designed specifically to include 
the number of possible confounders that need to be considered in MHO. 
For comparison of ETP and PTH approaches per B-C type in this study we focused on within-
group comparisons, with the main drawback being that numbers become smaller after 
subgrouping, especially when controlling for multiple confounders. For comparison of time to 
therapeutic success between ETP and PTH approaches per B-C type, the Mann-Whitney U test 
was utilised due to a very skewed dependent variable. Comparisons were not likely to show 
significance due to wide ranges (and even interquartile ranges) with large overlap. When 
attempting to compare time to therapeutic success per B-C type and as a function of stent and 






This thesis provides results to support the following conclusions: 
 
 Single operator cholangiopancreatoscopy, when added to ERCP, has significant 
clinical value in 63% of cases. In current endoscopic practice it is applied in the 
biliary tract (70%), pancreatic duct (25%) and both ducts (5%). Its clinical value lies 
firstly in the treatment of complex bile duct stones, and secondly as aid in the 
diagnosis of cystic pancreatic lesions and indeterminate biliary strictures.  
 
 The SOCP system has replaced the performance of cholangiopancreatoscopy by the 
mother-baby system and there is clear learning curve when first introduced.  
 
 Intraprocedural and postprocedural adverse events are increased when SOCP is added 
to an ERCP procedure.  
 
 In patients with malignant biliary obstruction the risk for adverse events, including 
pancreatitis and cholangitis, is increased after hilar compared to distal stenting.  
 
 Stent patency rates are lower for a single SEMS placed for MHO compared to distal 
malignant obstruction, with stenting for B-C IIIa types having the worst patency. 
 
 In patients with MHO undergoing palliative biliary drainage, ETP and PTH 
approaches have distinct strengths and weaknesses. Technical and therapeutic success 
rates are similar, while therapeutic success durability is better after an ETP approach. 
The two approaches have similar overall adverse event and cholangitis rates, while 





8 POINTS OF PERSPECTIVE 
 
Although many reports on SOCP performance regarding stone clearance rates and the accuracy of 
visual inspection/biopsy is available, quantification of the clinical value/impact of SOCP is dated 
and limited.86,87 Measurement of its clinical value was attempted in three small recent reports, 
restricted to the management of indeterminate biliary strictures.88–90 The grading scale used in 
study I is the only of its kind that allows for simultaneous assessment of SOCP therapeutic and 
diagnostic value but requires validation. Inclusion of more than one blinded reviewer will allow 
for calculation of interobserver variation (reproducibility) and its use in future studies will allow 
for measurement of criterion validity. 
Results from this thesis, highlighting the clinical value but also the increased risk for adverse 
events when SOCP is added to ERCP, corroborate the placement of SOCP in treatment 
algorithms in current guidelines for the treatment of ‘difficult’ bile duct stones and in the 
investigation of indeterminate strictures.29,174 A demonstratable learning curve cautions for its 
continued use in specialised high-volume centres where staff are adequately trained to prevent, 
recognise and treat associated adverse events. Future meticulous documentation of investigations 
to generate more evidence is a prerequisite for the firm establishment of this important procedure 
in pancreaticobiliary endoscopy algorithms. 
Although the robust data collected in the GallRiks registry (accounting for most confounders) 
allowed for comprehensive multivariate analysis of the risk of adverse events when SOCP is 
added to ERCP in study II, study III underscored the difficulties encountered in investigating 
stenting for MHO when making use of registry data. The GallRiks dataset is reviewed annually 
and adjustment of variables is performed accordingly, ensuring its continued excellence as data 
source in answering research questions pertaining to endoscopy in the hepatobiliary systems. 
Analysis of large population-based cohorts remains a platform for studies creating more robust 
data, as exemplified by the challenges encountered in study III leading to the creation of a 
multicentre registry dedicated to MHO in study IV. This registry currently offers analysis of 
outcomes after simultaneous or sequential combined ETP and PTH approaches, as well as 
mechanisms of recurrent biliary obstruction in the hepatic hilum. The combination of established 
national registries with a prospective randomised study design will increasingly in future make 
economic sense. 
The B-C classification system was designed for the operating surgeon to indicate the most distal 
extent of normal biliary mucosa available for anastomosis after curative resection in patients with 
CC.25 It is not optimal as a guide to the endoscopist or interventional radiologist as it does not 
give sufficiently detailed information on the extent of obstruction of sectoral ducts and does not 
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account for upstream liver functionality. A dedicated classification where not only the actual 
ductal topography is described, but in which functional parenchymal volumes beyond strictures 
are also quantified, would be of more value.  
The definition of therapeutic success after MHO drainage in published literature is based on 
decreased TB values which is used as a surrogate for the goal of treatment. In patients with MHO 
the treatment goal differs for patients undergoing preoperative stenting, patients planned for 
palliative oncological therapy and those with advanced disease where purely symptomatic relief 
is pursued. These differences need to be considered in future study designs and when comparing 
results between different patient populations. 
The definition and classification of recurrent biliary obstruction is not well defined in current 
literature.23,205,206 Mechanisms of recurrent obstruction, reasons for reintervention and treatment 
options at the time of reintervention differ somewhat for distal and hilar obstruction. Future 
studies and classification systems should explore and consider these differences. 
In study IV, patients with B-C IIIa types had 100% technical success after a single ETP 
procedure. They also had significantly more bilateral stents placed, a higher percentage of liver 
volume drained and trended towards a faster time to therapeutic success. The general dictum that 
B-C III-IV types should be drained via a percutaneous approach is challenged by our results 
showing ETP outperforming PTH in BC IIIa patients and being equal to PTH in BC IIIb and IV 
patients.103,133,174 Although small numbers limited statistical power in some analyses (especially 
B-C IIIb and IV), our data suggest that ETP drainage might be more successful in selected 
advanced B-C types. Future studies should endeavor to increase patient numbers and explore 
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